[go: up one dir, main page]

CA2736970A1 - Pyrimidinone derivatives for use as medicaments - Google Patents

Pyrimidinone derivatives for use as medicaments Download PDF

Info

Publication number
CA2736970A1
CA2736970A1 CA2736970A CA2736970A CA2736970A1 CA 2736970 A1 CA2736970 A1 CA 2736970A1 CA 2736970 A CA2736970 A CA 2736970A CA 2736970 A CA2736970 A CA 2736970A CA 2736970 A1 CA2736970 A1 CA 2736970A1
Authority
CA
Canada
Prior art keywords
compound
formula
optionally substituted
substituents selected
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2736970A
Other languages
French (fr)
Inventor
Benjamin Pelcman
Lloyd F. Mackenzie
Kang Han
Christian Krog-Jensen
Yuanlin Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biolipox AB
Original Assignee
Biolipox AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolipox AB filed Critical Biolipox AB
Publication of CA2736970A1 publication Critical patent/CA2736970A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is provided compounds of formula (I). wherein the dotted lines, R1, R2, R3, R4, R6, R7, m and n have meanings given in the description, and pharmaceutically acceptable derivatives thereof, which compounds are useful as inhibitors of PDE7 and, particularly, PDE4, and therefore of use e.g. in the treatment of diseases and conditions associated with inflammation.

Description

PYRIMIDINONE DERIVATIVES FOR USE AS MEDICAMENTS

Field of the Invention The present invention is directed to substituted pyrimidinone and/or tetrahydropyrimidinone compounds and their uses as therapeutic agents, especially PDE4 inhibitors.

Background of the Invention The Inflammatory Response (Inflammation) Inflammation is an essential localized host response to invading microorganisms or tissue injury which involves cells of the immune system. The classic signs of inflammation include redness (erythema), swelling (edema), pain and increased heat production (pyrema) at the site of injury. The inflammatory response allows the body to specifically recognize and eliminate an invading organism and/or repair tissue injury.
Many of the acute changes at the site of inflammation are either directly or indirectly attributable to the massive influx of leukocytes (e.g., neutrophils, eosinophils, lymphocytes, monocytes) which is intrinsic to this response. Leukocytic infiltration and accumulation in tissue results in their activation and subsequent release of inflammatory mediators such as LTB4, prostaglandins, TNF-a, IL-1(3, IL-8, IL-5, IL-6, histamine, proteases and reactive oxygen species for example.

Normal inflammation is a highly regulated process that is tightly controlled at several levels for each of the cell types involved in the response. For example, expression of the pro-inflammatory cytokine TNF-a is controlled at the level of gene expression, translation, post-translational modification and release of the mature form from the cell membrane. Many of the proteins up-regulated during inflammation are controlled by the transcription factor, NF-KB. Pro-inflammatory responses are normally countered by endogenous anti-inflammatory mechanisms such as generation of IL-10 or IL-4.,A
characteristic of a normal inflammatory response is that it is temporary in nature and is followed by a resolution phase which brings the state of the tissue back to its prior condition. The resolution phase is thought to involve up-regulation of anti-inflammatory mechanisms, such as IL-10, as well as down-regulation of the proinflammatory processes.

Inflammatory Disease Inflammatory disease occurs when an inflammatory response is initiated that is inappropriate and/or does not resolve in the normal manner but rather persists and results in a chronic inflammatory state. Inflammatory disease may be systemic (e.g.
lupus) or localized to particular tissues or organs and exerts an enormous personal and economic burden on society. Examples of some of the most common and problematic inflammatory diseases are rheumatoid arthritis, inflammatory bowel disease, psoriasis, asthma, chronic obstructive pulmonary disease, emphysema, colitis and ischemia-reperfusion injury.

A common underlying theme in inflammatory disease is a perturbation of the cellular immune response that results in recognition of host proteins (antigens) as foreign. Thus the inflammatory response becomes misdirected at host tissues with effector cells targeting specific organs or tissues often resulting in irreversible damage.
The self-recognition aspect of auto-immune disease is often reflected by the clonal expansion of T-cell subsets characterized by a particular T-cell receptor (TCR) subtype in the disease state. Often inflammatory disease is also characterized by an imbalance in the levels of T-helper (Th) subsets (i.e., Thl cells vs. Th2 cells).

Therapeutic strategies aimed at curing inflammatory diseases usually fall into one of two categories: (a) down-modulation of processes that are up-regulated in the disease state or (b) up-regulation of anti-inflammatory pathways in the affected cells or tissues. Most regimes currently employed in the clinic fall into the first category. Some examples of which are corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs).

Many of the tissue, cellular and biochemical processes which are perturbed in inflammatory disease have been elucidated and this has allowed the development of experimental models or assays to mimic the disease state. These in-vitro assays enable selection and screening of compounds with a high probability of therapeutic efficacy in the relevant inflammatory disease. Thus, currently employed assays used to model the importance of the activated leukocytes in the development of acute inflammation and maintenance of the chronic inflammatory state are assays monitoring leukocyte chemotaxis and cellular degranulation and cytokine synthesis and reactive oxygen species (ROS) production assays in vitro. Since a result of acute or chronic neutrophil activation is release of ROS with resultant tissue damage, an assay for scavengers of ROS allows detection of compounds with potential therapeutic efficacy.
Cellular assays to detect inhibitors of TNF-a release from stimulated macrophage or monocytic cells are an important component of an in vitro model for inflammation as this cytokine is upregulated and has been shown to contribute to the pathology in many inflammatory diseases. Since elevated cAMP in affected cells has been shown to modulate or dampen the inflammatory response, monitoring cellular cyclic AMP
(cAMP) levels, and the activity of pathways controlling cAMP levels allows for the detection of potential anti-inflammatory compounds. Assays may include monitoring the level of cAMP itself, phosphodiesterase activity, or changes in cAMP response element (CRE)-luciferase activity.

Cyclic Nucleotide Messengers and Phosphodiesterases The cyclic nucleotides, cyclic adenosine monophosphate (CAMP) and cyclic guanosine monophosphate (cGMP), play a key role in regulating cell function and phosphodiesterases (PDEs) provide the main route for the degradation of cyclic nucleotides. cAMP is now known to control the functional and genomic responses for a variety of cellular functions triggered by a wide array of receptors (Beavo, J.A. and Brunton, L.L., Nat. Rev. Mol. Cell Biol., 3, 710-718 (2002)). Local control of cAMP
signalling is affected by a complex pattern of localized synthesis, by adenylate cyclise (AC), and by phosphodiesterase (PDE)-mediated enzymatic degradation.

The PDEs are a family of enzymes that catalyze the hydrolysis of 3',5'-cyclic nucleotides to 5' nucleoside monophosphates, including the conversion of cAMP to AMP and cGMP
to GMP. PDE enzymes are collectively grouped as a superfamily of eleven different, but homologous, gene-families with a highly conserved catalytic domain (Soderling, S.H. and Beavo, J.A., Curr. Opin. Cell Biol., 12, 174-179 (2000)). At present twenty-one different mammalian PDE genes have been identified. Many of these genes are expressed in multiple isoforms either by differing initiation sequences or splicing patterns.
Differentiation of the enzymes can be achieved on the basis of substrate specificity, kinetic properties and sensitivity to regulatory molecules. PDEs in families 5, 6 and 9 specifically catalyze the hydrolysis of cGMP while PDEs 4, 7 and 8 are specific for cAMP. Enzymes belonging to the other PDE families (1, 2, 3, 10 and 11) catalyze the hydrolysis of both cAMP and cGMP with differing kinetics. Different PDE
isozymes can have specific tissue, cellular and subcellular distributions and more than one type of PDE
is usually present in any given cell. The types of PDEs= expressed in a cell, together with their relative proportions and subcellular localization, control the cyclic nucleotide phenotype of that cell.

The PDE4 enzyme is responsible for selective, high affinity hydrolytic degradation of the second messenger cAMP, has a low Michaelis constant and is sensitive to inhibition by rolipram. The PDE4 enzyme family consists of four genes, which produce 4 isoforms of the PDE4 enzyme (PDE4A, PDE4B, PDE4C, and PDE4D) (Wang et al., "Expression, Purification, and Characterization of human cAMP Specific Phosphodiesterase (PDE4) Subtypes A, B, C, and D, Biochem", Biophys. Res. Comm., 234, 320-324 (1997)).
Moreover, various splice variants of each PDE4 isoform have been identified and play a role in the compartmentalized cAMP signalling in cells (Houslay, M.D., Schafer, P., and Zhang, K.Y., Drug Discov. Today, 15;10(22):1503-19 (2005)). Recently, a number of selective PDE4 inhibitors have been discovered to have beneficial pharmacological effects resulting from PDE4 inhibition as shown in a variety of disease models (Torphy et al., Environ. Health Perspect., 102 Suppl. 10, 79-84, 1994; Duplantier et al., J. Med.
Chem., 39 120-125 (1996); Schneider et al., Pharmacol. Biochem. Behav., 50, (1995); Banner and Page, Br. J. Pharmacol., 114, 93-98 (1995); Barnette et al., J.
Pharmacol. Exp. Ther., 273, 674-679 (1995); Wright et al., "Differential in vivo and in vitro bronchorelaxant activities of CP-80633, a selective phosphodiesterase 4 inhibitor," Can.
J. Physiol. Pharmacol., 75, 1001-1008 (1997); Manabe et al., "Anti-inflammatory and bronchodilator properties of KF19514, a phosphodiesterase 4 and 1 inhibitor,"
Eur. J.
Pharmacol., 332, 97-107 (1997); and Ukita et al., "Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-py_ridylnaphthalene derivatives," J. Med. Chem., 42, 1088-1099 (1999)). Therefore, considerable interest exists in the discovery of additional selective inhibitors of PDE4.

Regulation of cAMP activity is important in many biological processes, including inflammation, depression and cognitive function. Chronic inflammation is a multitude of heterogeneous diseases characterized in part by activation of multiple inflammatory cells, particularly cells of lymphoid lineage (including T lymphocytes) and myeloid lineage (including granulocytes, macrophages, and monocytes). Activation of these inflammatory cells results in production and release of proinflammatory mediators, including cytokines and chemokines, such as tumor necrosis factor (TNF) and interleukin-1 (IL-1).
Discovery of a molecule that suppresses or inhibits such cellular activation and proinflammatory mediator release would be useful in the therapeutic treatment of inflammatory diseases.
Elevated cAMP levels suppress inflammatory cell activation. Increased cAMP
levels associated with PDE4 inhibition has therefore become a valid potential therapeutic approach to control inflammatory responses and disorders (Beavo et al., "Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action," Wiley and Sons, Chichester, pp. 3-14 (1990); Torphy et al., Drug News and Perspectives, 6, pp.
203-214 (1993); Giembycz et al., Clin. Exp. Allergy, 22, pp. 337-344 (1992);
and Sanz, M.J., Cortijo, J., Morcillo, E.J., Pharmacol Ther. 106(3):269-97 (2005)).

PDE4 inhibitors have recently shown clinical utility in mitigating the effects of the chronic pulmonary inflammatory diseases of asthma and chronic obstructive pulmonary disease (COPD). Roflumilast, a selective PDE4 inhibitor, demonstrated improvements in measures of airway function (forced expiratory volume in 1 second; FEV1, and peak expiratory flow; PEF) in mild asthmatics in a recently published clinical trial of 12 weeks duration (Bateman et al., Ann. Allergy Asthma Immunol., 96(5): 679-86 (2006)).
A
separate study with roflumilast also demonstrated improvements in airway hyper-responsiveness (AHR) to direct histamine provocation in a similar group of mild asthmatics in response to allergen challenge (Louw et al., Respiration, Sept.
5 2006).
Recently published results of a long term (6 month) study of cilomilast treatment in patients with COPD indicated that treatment with a selective PDE4 inhibitor arrested airway function (FEV1) decline in these patients and positively affected their quality of life as measured by the St. Georges Respiratory Questionnaire (Rennard et al., Chest, 129(1) 65-66 (2006)).

The clinical usefulness of PDE4 inhibition has also been demonstrated in disorders of the central nervous system. PDE4 inhibition by rolipram improves cognitive function in rodents and was developed as an antidepressant in humans. cAMP acts as a second messenger for neurotransmitters, and thus mediates their cellular responses.
The therapeutic effects of PDE4 inhibitors in cognition and depression likely originate from enhancement of the cAMP-dependent cellular responses.

The listing or discussion of an apparently prior-published document in this specification should not necessarily be taken as an acknowledgement that the document is part of the state of the art or is common general knowledge.

International patent application WO 2007/081570 discloses various compounds that may be useful in the treatment of cholesterol-related diseases. However, there is no disclosure that such compounds may be useful as phosphodiesterase 4 inhibitors, and therefore in the treatment of inflammation. Further, there is no specific disclosure of substituted pyrimidinones and tetrahydropyrimidinones.

International patent application WO 2006/124874 discloses a broad range of inter alia heterocyclic compounds that may be of use as inhibitors of B-Raf, and therefore of use in the treatment of cancer. There is no specific disclosure in that document of substituted pyrimidinones and tetrahydropyrimidinones.

US patents/applications US 6,162,927, US 2002/0055457, US 7,208,517 and US
2007/0203124, international patent applications WO 2002/11713, WO 2002/011713, WO
99/006397, WO 96/006095, WO 97/030045, WO 02/017912, WO 2005/115389 and WO
95/028926 and European patent EP 299 549 all disclose various compounds, including heterocycles, which may be useful as medicaments. However, there is no disclosure in any of these documents of substituted pyrimidinones and/or tetrahydropyrimidinones.

Further, US patent applications US 2003/0186943 and US 2004/0224316 and international patent applications WO 00/14083, WO 2004/031149, WO 2007/137181, WO 2004/091609 and WO 2004/016227 disclose inter alia piperidinones that may be useful in the treatment of inflammation-based diseases. However, these documents do not disclose substituted pyrimidinones and/or tetrahydropyrimidinones.

International patent application WO 01/68600 discloses various compounds, including pyrrolidinones and tetrahydropyrimidinoes, which may be useful in the treatment of inflammation-based diseases. However, there is no disclosure of pyrimidinones and tetrahydropyrimidinones substituted (via a linker) with certain heteroaryl or heterocycloalkyl groups.

International patent application WO 2007/110793 discloses various compounds, including piperidinones that may be useful as PDE inhibitors. However, there is no 3o disclosure in that document of pyrimidinones.
Disclosure of the Invention According to the invention, there is now provided a compound of formula (I), RNN -(R2 (R6) M

(R) n wherein:

the dotted lines each independently represent an optional bond (and when the dotted line between the carbon and nitrogen is present, then R2 is absent, and when the dotted line between the carbon and nitrogen is absent, then R2 is present);

m represents 0, 1, 2, 3, 4 or 5;
n represents 0, 1, 2 or 3;

at least one of R1 and, if present, R2 represents -A'-Tz-B' and the other (if present) represents R5;

R3 represents hydrogen, -OR4a, C,_12 alkyl (optionally substituted by one or more substituents selected from =0 and X) or -B2;

R4 and R41 independently represent hydrogen, C1.12 alkyl (optionally substituted by one or more substituents selected from =0 and X2) or -B3;

R5 represents hydrogen, C1_12 alkyl (optionally substituted by one or more substituents selected from =0 and X3) or -B 3a;

each R6 and each R7 independently represent X4, C1.12 alkyl (optionally substituted by one or more substituents selected from =0 and X5) or -B4; or any two R6 groups may be linked together to form a further ring, which is formed either by the two relevant groups being linked together by a direct bond or C1.5 alkylene;

A' represents C1_12 alkylene (optionally substituted by one or more substituents selected from =0 and X6);

TZ represents a direct bond, -N(R")- or -C(O)N(R12)_;

R"`' and R"'2 independently represent hydrogen, C1_12 alkyl (optionally substituted by one or more substituents selected from X) or -B5;

B1 represents:
1) a monocyclic 5-membered.heteroaryl group;
2) a polycyclic heteroaryl group;
3) a polycyclic aryl group; or 4) a heterocycloalkyl group, all four of which are optionally and independently substituted with one or more substituents selected from X6 and, in the case of heterocycloalkyl or any non-aromatic rings of a polycyclic aryl or heteroaryl group, =O;

B2, B3 and B3a independently represent aryl (optionally substituted by one or more substituents selected from X9), heterocycloalkyl (optionally substituted by one or more substituents selected from =0 and X10) or heteroaryl (optionally substituted by one or more substituents selected from X");

B4 and B5 independently represent heterocycloalkyl (optionally substituted by one or more substituents selected from =0 and X12);

X1, X2, X3, X4, X5, X6, X7, X8, X9, X10 X" and X12 independently represent B6, halo, -CN, -NO2, -Si(R8a)3, -OR 9a, -OC(O)-R 9b, -N(R9c)R9d, -C(O)R9e, -C(O)OR9f, -C(O)N(R99)R9h, -N(R9i)C(O)OR11b, -N(R9')C(O)R8c, -N(R9k)S(O)tR8d -S(O)tORBe, -S(O)pR8f, -S(O)tN(R9m)R9n, -N(R9p)C(O)N(R9')R9', -N(R9S)S(O)tOR89, -OC(O)N(R9t)R9u and/or -OS(O)tR8h;

R8a, R8b, R8d, R8f, R89 and R8h independently represent C1_12 alkyl optionally substituted by one or more substituents selected from =0 and E';
Be 9b 9d 9e 9n 9k 9n 9G 9r Rsc RR9a RR9c RRR9f R9g RR9f R9j RR9m RR9p RRR
R9t and R9u independently represent hydrogen or C1.12 alkyl optionally substituted by one or more substituents selected from =0 and E2; or any pair of R9C and R9d, R99 and R9h, R9m and R9n, R9q and R9r, and R9t and R9u may be linked together with the nitrogen atom to which they are attached to form a 3-to 8-membered ring, optionally containing one or more (e.g. one or two) unsaturations (e.g.
double bonds), optionally containing one or two (e.g. one) further heteroatoms (preferably selected from nitrogen and oxygen), and which ring is optionally substituted by one or more substituents selected from =0, halo and C1_6 alkyl optionally substituted by one or more halo atoms;

B6 represents C1_12 alkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or substituents selected from =0 and E3), aryl or heteroaryl (which latter two groups are optionally substituted by one or substituents selected from E4);

t represents, at each occurrence when used herein, 1 or 2;
p represents 0, 1 or 2;

E', E2, E3 and E4 independently represent halo, -CN, -NO2, -OR10a, -OC(O)-R'0b -N(R1oC)Riod -C(O)R1oe, -C(O)OR10f, -C(O)N(R1o9)R1Oh _N(R10)C(O)OR'1a, -N(R'oj)C(0)R11b _N(Rbok)S(O)t1R11o -S(O)t,OR11d -S(O)p1R>>e _S(O)t1N(Riom)RiOn -N(R10p)C(O)N(R10q)R10r, -N(R10S)S(O)t1OR11f, -OC(O)N(R10)R10u, -OS(O)t1R1 and/or -Si(R11h)3;

Rtoa Riob Rtoc Rlod Rioe R1of R109 Rton R10 R10j R1ok Worn Rton Rio Rioq Rior R10s Riot R10u R1 lb and R"d independently represent hydrogen or C1.3 alkyl optionally substituted by one or more halo atoms;

3o R"a, R11C, R7e, R"f R119 and R1 1h independently represent C1.3 alkyl optionally substituted by one or more halo atoms;

t1 represents, at each occurrence when used herein, 1 or 2;
p1 represents 0, 1 or 2, or a pharmaceutically acceptable salt thereof, which compounds are hereinafter referred to as the "compounds of the invention".
Pharmaceutically-acceptable salts include acid addition salts and base addition salts.
Such salts may be formed by conventional means, for example by reaction of a free acid or a free base form of a compound of formula I with one or more equivalents of an appropriate acid or base, optionally in a solvent, or in a medium in which the salt is insoluble, followed by removal of said solvent, or said medium, using standard techniques (e.g. in vacuo, by freeze-drying or by filtration). Salts may also be prepared by exchanging a counter-ion of a compound of the invention in the form of a salt with another counter-ion, for example using a suitable ion exchange resin.

Compounds of the invention may contain double bonds and may thus exist as E
(entgegen) and Z (zusammen) geometric isomers about each individual double bond. All such isomers and mixtures thereof are included within the scope of the invention.

Compounds of the invention may also exhibit tautomerism. All tautomeric forms and mixtures thereof are included within the scope of the invention.

Compounds of the invention may also contain one or more asymmetric carbon atoms and may therefore exhibit optical and/or diastereoisomerism. Diastereoisomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation. The various stereoisomers may be isolated by separation of a racemic or other mixture of the compounds using conventional, e.g. fractional crystallisation or HPLC, techniques. Alternatively the desired optical isomers may be made by reaction of the appropriate optically active starting materials under conditions which will not cause racemisation or epimerisation (i.e. a 'chiral pool' method), by reaction of the appropriate starting material with a 'chiral auxiliary' which can subsequently be removed at a suitable stage, by derivatisation (i.e. a resolution, including a dynamic resolution), for example with a homochiral acid followed by separation of the diastereomeric derivatives by conventional means such as chromatography, or by reaction with an appropriate chiral reagent or chiral catalyst all under conditions known to the skilled person.
All stereoisomers and mixtures thereof are included within the scope of the invention.

Unless otherwise specified, Cl., alkyl, and C1_q alkylene, groups (where q is the upper limit of the range), defined herein may be straight-chain or, when there is a sufficient number (i.e. a minimum of two or three, as appropriate) of carbon atoms, be branched-chain, and/or cyclic (so forming, in the case of alkyl, a C3_q cycloalkyl group or, in the case of alkylene, a C3_q cycloalkylene group). Further, when there is a sufficient number (i.e. a minimum of four) of carbon atoms, such groups may also be part cyclic.
Further, unless otherwise specified, such alkyl groups may also be saturated or, when there is a sufficient number (i.e. a minimum of two) of carbon atoms and unless otherwise specified, be unsaturated (forming, for example, in the case of alkyl, a C2.q alkenyl or a C2-q alkynyl group or, in the case of alkylene, a C2_q alkenylene or a C2_q alkynylene group). In the case of alkylene groups, it is preferred that they are acyclic and/or straight-chain, but may be saturated or unsaturated.

The term "halo", when used herein, includes fluoro, chloro, bromo and iodo.
Heterocycloalkyl groups that may be mentioned include non-aromatic monocyclic, bicyclic and tricyclic (e.g. monocyclic or bicyclic) heterocycloalkyl groups (which groups may further be bridged) in which at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom), and in which the total number of atoms in the ring system is between three and twelve (e.g. between five and ten).
Further, such heterocycloalkyl groups may be saturated or unsaturated containing one or more double and/or triple bonds, forming for example a C2_q heterocycloalkenyl (where q is the upper limit of the range) or a C7_q heterocycloalkynyl group. C2_q heterocycloalkyl groups that may be mentioned include 7-azabicyclo-[2.2.1]heptanyl, 6-azabicyclo[3.1.1]heptanyl, 6-azabicyclo[3.2. 1 ]-octanyl, 8-azabicyclo[3.2.1]octanyl, aziridinyl, azetidinyl, dihydropyranyl, dihydropyridyl, dihydropyrrolyl (including 2,5-dihydropyrrolyl), dioxolanyl (including 1,3-dioxolanyl), dioxanyl (including 1,3-dioxanyl and 1,4-dioxanyl), dithianyl (including 1,4-dithianyl), dithiolanyl (including 1,3-dithiolanyl), imidazolidinyl, imidazolinyl, morpholinyl, 7-oxabicyclo[2.2.1 ]heptanyl, 6-oxabicyclo[3.2.1 ]-octanyl, oxetanyl, oxiranyl, piperazinyl, piperidinyl, pyranyl, pyrazolidinyl, pyrrolidinonyl, pyrrolidinyl, pyrrolinyl, quinuclidinyl, sulfolanyl, 3-sulfolenyl, tetrahydropyranyl, tetrahydrofuranyl, tetrahydropyridyl (such as 1,2,3,4-tetrahydropyridyl and 1,2,3,6-tetrahydropyridyl), thietanyl, thiiranyl, thiolanyl, thiomorpholinyl, trithianyl (including 1,3,5-trithianyl), tropanyl and the like. Substituents on heterocycloalkyl groups may, where appropriate, be located on any atom in the ring system including a heteroatom. Further, in the case where the substituent is another cyclic compound, then the cyclic compound may be attached through a single atom on the heterocycloalkyl group, forming a so-called "spiro"-compound. The point of attachment of heterocycloalkyl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system. Heterocycloalkyl groups may also be in the N- or S- oxidised form.
Most preferably, heterocycloalkyl groups that may be mentioned include 5- or 6-membered monocyclic heterocycloalkyl groups.

For the avoidance of doubt, the term "bicyclic" (e.g. when employed in the context of heterocycloalkyl groups) refers to groups in which the second ring of a two-ring system is formed between two adjacent atoms of the first ring. Bicyclic also includes bridged bicyclic groups. The term "bridged" (e.g. when employed in the context of heterocycloalkyl groups) refers to monocyclic or bicyclic groups in which two non-adjacent atoms are linked by either an aikylene or heteroalkylene chain (as appropriate).
Aryl groups that may be mentioned include C6_14 (such as C6.13 (e.g. C6-1o)) aryl groups.
Such groups may be polycyclic (e.g. monocyclic or bicyclic) and have between 6 and 14 ring carbon atoms, in which at least one ring is aromatic. C6.14 aryl groups include phenyl, naphthyl and the like, such as 1,2,3,4-tetrahydronaphthyl, indanyl, indenyl and fluorenyl. The point of attachment of aryl groups may be via any atom of the ring system.
However, when aryl groups are bicyclic or tricyclic, they are linked to the rest of the molecule via an aromatic ring.

Heteroaryl groups that may be mentioned include those which have between 5 and (e.g. 10) members. Such groups may be monocyclic, bicyclic or tricyclic, provided that at least one of the rings is aromatic and wherein at least one (e.g. one to four) of the atoms in the ring system is other than carbon (i.e. a heteroatom). Heteroaryl groups that may be mentioned include acridinyl, benzimidazolyl, benzodioxanyl, benzodioxepinyl, benzodioxolyl (including 1,3-benzodioxolyl), benzofuranyl, benzofurazanyl, benzothiazolyl, benzoxadiazolyl (including 2,1,3-benzoxadiazolyl), benzoxazinyl (including 3,4-dihydro-2H-1,4-benzoxazinyl), benzoxazolyl, benzomorpholinyl, benzoselenadiazolyl (including 2,1,3-benzoselenadiazotyl), benzothiadiazolyl (including 2,1,3-benzothiadiazolyl), benzothienyl, carbazolyl, chromanyl, cinnolinyl, furanyl, imidazolyl, imidazopyridyl (including imidazo[4,5-b]pyridyl, imidazo[5,4-b]pyridyl and imidazo[1,2-a]pyridyl), indazolyl, indolinyl, indolyl, isobenzofuranyl, isochromanyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiaziolyl, isothiochromanyl, isoxazolyl, naphthyridinyl (including 1,6-naphthyridinyl or, preferably, 1,5-naphthyridinyl and 1,8-naphthyridinyl), oxadiazolyl (including 1,3,4-oxadiazolyl), oxazolyl, phenazinyl, phenothiazinyl, phthalazinyl, pteridinyl, purinyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, quinolizinyl, quinoxalinyl, tetrahydroiso-quinolinyl (including 1,2,3,4-tetrahydroisoquinolinyl and 5,6,7,8-tetrahydroisoquinolinyl), tetrahydroquinolinyl (including 1,2,3,4-tetrahydroquinolinyl and 5,6,7,8-tetrahydroquinolinyl), tetrazolyl, thiadiazolyl (including 1,3,4-thiadiazolyl), thiazolyl, oxazolopyridyl (including oxazolo[4,5-b]pyridyl, oxazolo[5,4-b]pyridyl and, in particular, oxazolo[4,5-c]pyridyl and oxazolo[5,4-c]pyridyl), thiazolopyridyl (including thiazolo[4,5-b]pyridyl, thiazolo[5,4-b]pyridyl and, in particular, thiazolo[4,5-c]pyridyl and thiazolo[5,4-c]pyridyl), thiochromanyl, thienyl, triazolyl (including 1,2,3-triazolyl and 1,2,4-triazolyl) and the like. Substituents on heteroaryl groups may, where appropriate, be located on any atom in the ring system including a heteroatom. The point of attachment of heteroaryl groups may be via any atom in the ring system including (where appropriate) a heteroatom (such as a nitrogen atom), or an atom on any fused carbocyclic ring that may be present as part of the ring system. However, when heteroaryl groups are polycyclic, they are preferably linked to the rest of the molecule via an aromatic ring.
Heteroaryl groups may also be in the N- or S- oxidised form.

Heteroatoms that may be mentioned include phosphorus, silicon, boron, tellurium, selenium and, preferably, oxygen, nitrogen and sulphur.

For the avoidance of doubt, in cases in which the identity of two or more substituents in a compound of the invention may be the same, the actual identities of the respective substituents are not in any way interdependent. For example, in the situation in which B2 and B3 both represent an aryl group optionally substituted as hereinbefore defined, the aryl groups in question may be the same or different. Similarly, when groups are substituted by more than one substituent as defined herein, the identities of those individual substituents are not to be regarded as being interdependent. For example, when X' represents two optional substituents, the identities of the two X' groups are not to be regarded as being interdependent. Likewise, when B2 represents e.g. an aryl group substituted by one or more (e.g. two) X9 groups, the identities of the two X9 groups are not to be regarded as being interdependent.

For the avoidance of doubt, where it is stated that the dotted lines may each independently represent an optional bond, we mean that when the optional bond is present (together with the existing bond represented by an unbroken line) so forming a carbon-nitrogen double bond or carbon-carbon double bond (as appropriate).
Similarly, where the optional bond represented by the dotted line is absent, only a single bond between the relevant carbon-nitrogen and carbon-carbon bond (represented by the unbroken line) is present. Hence, the following compounds of formula I are included:

RNNR

RN~N R R RI N N N IN
(Rsm \
(R6)m \ (R~m (R%
(R7), (R)n la Ib Ic Id For the avoidance of doubt, where the dotted line between carbon and the nitrogen to which R2 is bound represents a bond (so forming a double bond between carbon and the nitrogen to which R2 is bound), then R2 is absent. Similarly, where the dotted line between carbon and the nitrogen to which R2 is bound does not represent a bond (thus resulting in a single bond between carbon and the nitrogen to which R2 is bound), then R2 is present.

Particularly preferred compounds of formula I, include those of formula Ic depicted above, i.e. the following compounds in which the dotted line that is not attached to a nitrogen atom represents a double bond:
0 p RN NCR 2 RN,J'N, R2 (R)m (R)m (R)n (R)n which the skilled person will appreciate may be depicted as either one of the above two compounds (in view of the fact that it is specified herein that either one of R1 and, when present, R2 may represent certain/the same integers).

For the avoidance of doubt, -(R7), represents between one and three optional (i.e. R7 may not be present) substituents (as n may be 0, 1, 2 or 3), which may be attached to any one of the three free positions of the requisite benzene ring of the compound of formula I (to which -(R 7)n is bound). Similarly, -(R)m represents between one and five optional (i.e. R6 may not be present) substituents, which may be attached to any one of the free positions of the ring to which -(R6)m ring is attached, as permitted by the standard valencies of the relevant atoms in the rings.

For the avoidance of doubt, when a term such as "X' to X12i is employed herein, this will be understood by the skilled person to mean X', X2, X3, X4, X5, X6, X7, X8, X9, X10, X" and X12 inclusively.

Compounds of the invention that may be mentioned include those in which:
R80 represents C1_12 alkyl optionally substituted by one or more substituents selected from =0 and E';
R"d represents C1.3 alkyl optionally substituted by one or more halo atoms;
when an alkyl group mentioned herein is substituted with halo, then that halo group is preferably fluoro;
C1.12 alkyl groups mentioned herein are more preferably C1_6 alkyl groups.

Other compounds of the invention that may be mentioned include those in which:
there is a maximum of one R6 group (i.e. m represents 0 or 1) present;
there are not two R6 groups attached to the same carbon atom (of the requisite pyrimidinone ring of formula I);
any two R6 groups present on the same carbon atom are not linked together;
any two R6 groups are not linked together; and/or m represents 0 (i.e. there are no R6 substituents present).

It is stated above that compounds of the invention that may be mentioned include those in which there are not two R6 groups attached to the same carbon atom and any two R6 groups present on the same carbon atom are not linked together; hence, in this instance there is no tetra-substituted carbon atom in the main pyrimidinone ring of the compound of formula I.

Preferred compounds of the invention that may be mentioned include those in which:
the dotted lines either both represent bonds or, more preferably, are both not present (in another preferred embodiment, one double bond is present between two carbon atoms of the requisite pyrimidinone ring of the compound of formula I);
when B' represents a polycyclic aryl group, then it is preferably bicyclic (e.g. a naphthyl or tetrahydronaphthyl group), in which the point of attachment (to the Tz moiety) may be via an aromatic or non-aromatic ring;
when B1 represents a polycyclic (e.g. bicyclic) heteroaryl group, the ring attached to the Tz group is a six-membered or, more preferably, five-membered heterocycloalkyl or heteroaryl ring of the polycycle;

B1 preferably represents a monocyclic 5-membered heteroaryl group; a polycyclic (e.g.
bicyclic) heteroaryl group; or a heterocycloalkyl group, all of which are optionally substituted as defined herein;
when R3 is -OR 4a, at least one of -R4 and -R 4a is other than acyclic C1_12 alkyl (e.g.
methyl);
when R3 is -OR 4a, at least one of -R4 and -R 41 is cycloalkyl or heterocycloalkyl as defined herein;
when R3 is -OR 4a, at least one of -R4 and -R 4a (e.g. R4a) is other than acyclic C1_12 alkyl (for example, R4a is cycloalkyl or heterocycloalkyl as defined herein) and the other (e.g.
R4) represents acyclic C1.12 (e.g. C1.6) alkyl.

Preferred compounds of the invention include those in which:
m represents 3, preferably, 2, or, more preferably, 0 or 1;
n represents 2 or, preferably, 0 or 1;
R' represents -A'-Tz-B';
R3 represents hydrogen, C1.12 alkyl (optionally substituted by one or more substituents selected from =0 and X') or, preferably, -OR4a;
R4 and R41 independently represent C1.12 alkyl (optionally substituted by one or more substituents selected from =0 and X2) or -B3;
when R4 and R4a independently represent C1.12 alkyl, then they may represent acyclic C1.6 alkyl or, preferably, a C3.8 (e.g. C5_6) cycloalkyl group (both of which may be optionally substituted as defined herein);
for instance, certain compounds of formula I in which one of R4 and R4a is acyclic (e.g.
acyclic C1_6 alkyl as defined herein) and the other is acyclic (e.g. acyclic C1.6 alkyl as defined herein) or, preferably, cyclic (e.g. a C3.8 (e.g. C5_6) cycloalkyl group), i.e. most preferably, one of R4 and R4a is acyclic and the other is preferably cyclic;
R41 more preferably represents a 5- or 6-membered (e.g. 5-membered) heterocycloalkyl group (e.g. in which the heterocycloalkyl group contains two or preferably one heteroatom, preferably selected from nitrogen or, especially oxygen) or, R4a more preferably represents C3_8 cycloalkyl (e.g. C5_6 cycloalkyl), which heterocycloalkyl and cycloalkyl groups are optionally substituted as hereinbefore defined, but which are preferably unsubstituted;
R4 more preferably represents C1_12 alkyl, such as acyclic C1_6 alkyl (e.g.
C1.3 alkyl, scuh as methyl), which group may be substituted as defined herein, but is preferably unsubstituted;
R5 represents C1.6 (e.g. C1.3) alkyl (optionally substituted by one or more substituents selected from =0 and X) or, preferably, hydrogen;

each R6 and each R7 independently represent X4 or C1_6 (e.g. C1_3) alkyl (optionally substituted by one or more substituents selected from =0 and X);
any two R6 groups are not linked together;
A' represents C1.6 (e.g. C1.3) alkylene (e.g. methylene) (optionally substituted by one or more substituents selected from =0 and X6; but preferably unsubstituted);
R"'' and RW2 independently represent C1.3 alkyl (e.g. methyl) or, preferably, hydrogen;
B1 represents a 5-membered heteroaryl group or, preferably, a polycyclic (e.g.
bicyclic) heteroaryl group (both of which are) optionally substituted with one or more substituents selected from X8;
1o when B1 represents a 5-membered heteroaryl group, then it preferably contains one or two heteroatoms, preferably selected from nitrogen, oxygen and sulfur (more preferably, it contains at least one nitrogen heteroatom and preferably another one heteroatom, i.e.
two heteroatoms in total);
when B1 represents a 5-membered heteroaryl group, then it may be unsubstituted, but is preferably substituted by one or more (e.g. one or two) X8 substituents (e.g.
e.g. halo (e.g. F or Cl), C1.3 alkyl (e.g. CH3 or CF3) or -OR9e (e.g. OCH3 or OCF3), or, more preferably, the X8 substituents are e.g. halo or C1.3 alkyl, e.g. chloro or methyl);
when B' represents a polycyclic (e.g. bicyclic) heteroaryl group, then the point of attachment of that polycyclic heteroaryl group to the Tz group is via a heterocyclic (e.g.
heteroaromatic) ring of that polycyclic group (most preferably the point of attachment is via a 5-membered heteroaromatic ring);
B2 B3 B3a independently represent phenyl (optionally substituted by one or more substituents selected from X), a 5- or 6-membered heterocycloalkyl group (optionally substituted by one or more substituents selected from =0 and X10) or a 5- or 6-membered heteroaryl group (optionally substituted by one or more substituents selected from X");
when B2, B3 and B3a represent a 5- or 6-membered heterocycloalkyl or heteroaryl group, then, in each case, the heteroatom(s) is/are preferably selected from oxygen and nitrogen (further, in the case where B2, B3 and B3a represent heteroaryl, then the 3o heteroatom(s) may also be selected from sulfur);
when B2, B3 and B3a represent a 5- or 6-membered heterocycloalkyl or heteroaryl group, then those groups contain two or, preferably, one heteroatom(s);
B4 and B5 independently represent a 5- or 6-membered heterocycloalkyl group (optionally substituted by one or more substituents selected from =0 and X12);
when B4 and B5 represent a 5- or 6-membered heterocycloalkyl group, then the heteroatom(s) is/are preferably selected from oxygen and nitrogen;

when B4 and B5 represent a 5- or 6-membered heterocycloalkyl group, then those groups contain two or, preferably, one heteroatom(s);
B3 represents a five-membered heteroaryl or heterocycloalkyl group, in which the heteroatom is preferably oxygen (so forming, e.g. a furanyl or tetrahydrofuranyl group);
X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X" and X12 independently represent B6, preferably, -C(O)OR9f, -S(O)tN(R9m)R9n, -N(R9k)S(O)tR8d and/or, more preferably, -CN, -NO2, halo (e.g. fluoro), -OR9a, -N(R9c)R9d, -C(O)N(R99)R9h and/or -N(R9j)C(O)Rsc;
X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X" and X12 (especially X8) independently represents, at each occurrence when used herein, B6, -CN, -NO2, halo (e.g.
fluoro), -OR 9a, -N(R9c)R9d, -C(O)N(R99)R9' and/or -N(R9j)C(O)R8c;
RBa, R8b, Red, R8e, R8f, R89 and R8h independently represent C1_6 (e.g. C1.3) alkyl optionally substituted by one or more substituents selected from E';
RBc, R9a, R9b, R9c, R9d, R9e, R9f, R99, R9h, R9', R9j, R9k, R9m, R9n, R9P, R9G, R91, R9s, R9t and R9u independently represent hydrogen or C1.6 (e.g. C1.4 or, preferably, C1.3) alkyl (e.g. t-butyl or, preferably, methyl) optionally substituted by one or more substituents selected from E2; or any pair of R9c and R9d, R99 and R9h, R9rti and R9n, R9q and R9r, and R9t and R9u may be linked together with the nitrogen atom to which they are attached to form a 5-or 6-membered ring, optionally containing one or two double bonds, optionally containing one further nitrogen or oxygen heteroatom, and which ring is optionally substituted by one or more substituents selected from fluoro, =0 and C1_3 alkyl optionally substituted by one or more fluoro atoms (more preferably, any R9 pair are not linked together);
B6 represents (acyclic or, e.g. preferably, cyclic) C3.8 alkyl, 5- or 6-membered heterocycloalkyl (both of which are optionally substituted by one or more E3 substituents), preferably, heteroaryl or, more preferably, aryl (e.g. phenyl), which latter two groups are optionally substituted by one or more E4 substituents;
E', E2, E3 and E4 independently represent -N(R10k)S(O)t1R1I , -S(O)t,N(R10m)R1On preferably, -NO2, -C(O)OR10f, or, more preferably, halo, -CN, -OR1oa -N(R1oc)R1od -C(O)N(R109)R1 Oh and/or -N(R10j)C(O)R1'b (particularly preferred groups, e.g.
E2 groups, include -C(O)N(R109)R1 oh);
R1oa R1ob, R1oc, R1od R10e R10f R109 R1oh R10' , R10j R10k, R10m R1on R10 , R1oq R10r R105 R1of R1ou and Rub independently represent hydrogen, -CH3 or -CF3 (e.g. R10 and R1oh independently represent hydrogen);
R1 la R11c R1 1d R1 le R11', R119 and R1 1h independently represent -CH3 or -CF3.

When B' represents a monocyclic 5-membered heteroaryl group, preferred groups include represents pyrazolyl, thiazolyl, furanyl, imidazolyl and oxazolyl.
Particularly preferred groups are 1,3-dimethyl-pyrazol-5-yl and 2-chloro-thiazol-5-yl.

When B' represents a polycyclic (e.g. bicyclic) heteroaryl group, preferred groups include optionally substituted (e.g. by X8) benzoxazolyl (e.g. 2-benzoxazolyl), benzimidazolyl (e.g. 2-benzimidazolyl), benzofuranyl (e.g. 2-benzofuranyl), indolyl (e.g. 3-indolyl), benzothienyl (e.g. 3-benzothienyl), benzothiazolyl (e.g. 2-benzothiazolyl), benzotriazolyl (e.g. benzo-1,2-3-triazol-1-yl) and oxazolopyridinyl (e.g. oxazolo[5,4-b]pyridinyl, oxazolo[5,4-c]pyridinyl, oxazolo[4,5-b]pyridinyl or oxazolo[4,5-c]pyridinyl).
Particularly preferred bicyclic heteroaryl groups include benzimidazolyl (e.g. 2-benzimidazolyl) or, preferably, benzoxazolyl (e.g. 2-benzoxazolyl) groups. Particularly preferred groups are 5-fluoro-benzoxazol-2-yl, 1-[-C(O)Ot-butyl]-benzimidazol-2-yl, 5-methoxy-benzofuran-2-yl, unsubstituted benzimidazol-2-yl, 4-fluoro-benzoxazol-2-yl, 7-fluoro-benzoxazol-2-yl, 6-fluoro-benzoxazol-2-yl, 5-fluoro-benzoxazol-2-yl, 4-cyano-benzoxazol-2-yl and 7-cyano-benzoxazol-2-yl.

Preferred optional substituents on B1 groups include -C(O)O-C,_4 alkyl (e.g.
-C(O)O-t-butyl); or, preferably, C1.4 alkyl (e.g. methyl) optionally substituted by one or more halo atoms (so forming, for example, a difluoromethyl or trifluoromethyl group);
halo (e.g. chloro or fluoro); -CN; and -O-C1 ~ alkyl (e.g. methoxy) optionally substituted by one or more substituents selected from -C(O)N(R18)2 (in which R18 is preferably hydrogen; so forming, for example an acetamidoxy substituent) or, more preferably, halo (so forming, for example, a difluoromethoxy or trifluoromethoxy group).
Particularly preferred such substituents include fluoro atoms. Further, such substituents may, for example, when substituted on a benzimidazolyl (e.g. 2-benzimidazolyl) or benzoxazolyl (e.g. 2-benzoxazolyl) group, be in the 4- to 7- (e.g. 4-, 7- or, preferably, 5-) position.

More preferred compounds of the invention include those in which:
m represents 0;
n represents 0;
the dotted lines both represent bonds (i.e. there are two double bonds in the requisite 6-membered ring of formula I, thereby forming a pyrimidinone), are both not present (i.e.
there are only single bonds in the requisite 6-membered ring of formula I, thereby forming a tetrahydropyrimidinone), or, preferably, one of the dotted lines (e.g. the dotted line between two carbon atoms) represents a bond (i.e. such that there is one double bond present between two carbon atoms in the requisite 6-membered ring of formula I, thereby forming a 2-oxo-2,3-dihydro-pyrimidin-1 -yl group);
R3 represents -OR 41;
R4a preferably represents furanyl (e.g. 3-furanyl), tetrahydrofuranyl (e.g. 3-tetrahydrofuranyl) or, more preferably, cyclopentyl;
R4 represents trifluoromethyl, difluoromethyl or, preferably, methyl;
R5 represents H;
A' represents -CH2-;
Tz represents a direct bond;
1o B' (preferably unsubstituted or, more preferably, substituted with at least one group selected from X8) represents pyrazolyl (e.g. 5-pyrazolyl) or, preferably, benzofuranyl (e.g.
3-benzofuranyl or 2-benzofuranyl), benzoxazolyl (e.g. 2-benzoxazolyl), benzimidazolyl (e.g. 2-benzimidazolyl), thienyl (e.g. 2-thienyl), furanyl (e.g. 2-furanyl), imidazolyl (e.g. 2-imidazolyl), oxazolyl (e.g. 2-oxazolyl), thiazolyl (e.g. e.g. 5-thiazolyl or, preferably, 2-thiazolyl), indofyl (e.g. 3-indolyl or 2-indolyl),, benzothienyl (e.g. 3-benzothienyl or 2-benzothienyl) or benzotriazolyl (e.g. 1 -benzotriazolyl or 2-benzotriazolyl);
X$ represents C,_2 alkyl (e.g. methyl), preferably, -C(O)O-C1_4 alkyl (e.g. -C(O)O-t-butyl);
or, more preferably, -OCH3; halo (e.g. -F and/or -Cl); -CH3; -NO2; -CN; -CF3 and -O-CH2-C(=O)-NH2.
Particularly preferred compounds of the invention include those in the following list:
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(7-methoxy-2-benzofurylmethyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(7-fluoro-2-benzofurylmethyl)tetrahydropyri-midin-2-one;
1-(2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5,6-dimethyl-2-benzimidazolylmethyl)tetra-hydropyrimidin-2-one;
1-(2-benzofurylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(2-th ienylmethyf )tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(2-furylmethyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-imidazolyimethyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(1-methyl-2-imidazolylmethyl)tetrahydropyrimi-din-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-oxazolylmethyl)tetrahydropyrimidin-2-one;

5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-thiazolylmethyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-indolylmethyl)tetrahydropyrimidin-2-one;
1-(3-benzothienylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
1-(2-benzothiazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-methyl-2-benzoxazolylmethyl)tetrahydro-pyrimidin-2-one;
1-(6-chloro-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-methyl-2-benzoxazolylmethyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(6-methyl-2-benzoxazolylmethyl)tetrahydro-pyrimidin-2-one;
1-(1-benzotriazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-nitro-2-benzoxazolylmethyl)tetra hyd ropy rim i-din-2-one;
1-(5-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyri-midin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-fluoro-2-benzoxazolylmethyl)tetrahydropyri-midin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-trifluoromethyl-2-benzoxazolylmethyI)tetra-hydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-methyl-2-benzoxazolylmethyl)tetrahydropyri-midin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-methoxy-2-benzoxazolylmethyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-methoxy-2-benzoxazolylmethyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-fluoro-2-benzoxazolylmethyl)tetrahydropyri-midin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-fluoro-2-benzoxazolylmethyl)tetrahydropyri-midin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyri-midin-2-one;

1-(7-chloro-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyri-midin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-trifluoromethyl-2-benzoxazolylmethyl)tetra-hydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(5-methoxy-2-benzofurylmethyl)tetrahydropyri-midin-2-one;
1-(2-benzimidazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(1-methyl-2-benzimidazolylmethyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(5,6-dichloro-2-benzimidazolylmethyl)tetra-hydropyrimidin-2-one;
1-(4-acetamidoxy-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetra-hydropyrimidin-2-one;
31(7-acetamidoxy-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetra-hydropyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-difluoromethoxyphenyl)tetra-hydropyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmeth yl)-5-(3-cyclopentyloxy-4-trifluorometh oxyphenyl)tetra-hydropyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-[4-d ifIuoromethoxy-3-(3-tetrahydrofuranyloxy)-phenyl]tetrahydropyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-[4-methoxy-3-(3-tetrahydrofuranyloxy)phenyl]-tetrahydropyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-[4-trifluoromethoxy-3-(3-tetrahydrofuranyloxy)-phenyl]tetrahydropyrimidin-2-one.

Further particularly preferred compounds of the invention include those in the following list:

5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-methoxy-2-benzofurylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-fluoro-2-benzofurylmeth yl)pyrimidin-2-one;
1-(2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5,6-dimethyl-2-benzimidazolylmethyl)pyrimidin-2-one;
1-(2-benzofurylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-thienylmethyl)pyrimidin-2-one;

5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-furylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-imid azolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(1-methyl-2-imidazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-oxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-thiazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-indolylmethyl)pyrimidin-2-one;
1-(3-benzothienylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
1-(2-benzothiazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-methyl-2-benzoxazolylmethyl)pyrimidin-2-one;
1-(6-chloro-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-methyl-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(6-methyl-2-benzoxazolylmethyl)pyrimidin-2-one;
1-(1-benzotriazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-nitro-2-benzoxazolylmethyl)pyrimidin-2-one;
1-(5-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one 5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-fluoro-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-trifluoromethyl-2-benzoxazolylmethyl)pyrimi-din-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-methyl-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-methoxy-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-methoxy-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-fluoro-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-fluoro-2-benzoxazolylmethyl)pyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one 1-(7-chloro-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-trifluoromethyl-2-benzoxazolylmethyl)pyrimi-din-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-methoxy-2-benzofurylmethyl)pyrimidin-2-one;
1-(2-benzimidazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;

5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(1 -methyl-2-benzimidazolylmethyl)pyrimid in-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5,6-dichloro-2-benzimidazolylmeth yl)pyrimidin-2-one;
1-(4-acetamidoxy-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimi-din-2-one;
1-(7-acetamidoxy-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimi-din-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-difluoromethoxyphenyl)pyrimi-din-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-trifluoromethoxyphenyl)pyrimi-din-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-[4-difluoromethoxy-3-(3-furanyloxy)phenyl]pyrimidin-2-one;
1 -(4-cya no-2-benzoxazo lylmethyl)-5-[4-methoxy-3-(3-fu ranyloxy)phenyl]pyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-[4-trifluoromethoxy-3-(3-furanyioxy)phenyl]pyrimi-din-2-one.

Particularly preferred compounds of the invention include those of the examples described hereinafter.

Compounds of the invention may be made in accordance with techniques that are well known to those skilled in the art, for example as described hereinafter.

According to a further aspect of the invention there is provided a process for the preparation of a compound of formula I which process comprises:

(i) reaction of a compound of formula II, O

HNAN ,(R

(R6)m I I

or a protected derivative thereof, wherein R2, R3, R4, R6, R7 and the dotted lines are as hereinbefore defined, with a compound of formula IV, B'-TZ-A'-L' I I I

wherein B', TZ and A' are as hereinbefore defined, and L' represents a suitable leaving group, such as a sulfonate group or, more preferably an iodo, bromo or chloro group, in the presence of a base, such as a strong base, for instance an alkali metal-based base such as NaH and/or KO-tent-butyl, optionally in the presence of an additive (for example, a sodium or potassium co-ordinating agent, such as a crown ether (e.g. 15-crown-5)), for example in the presence of a suitable solvent, such as a polar aprotic solvent (e.g.
tetrahydrofuran or diethyl ether), for example at sub-ambient temperatures (e.g. 0 C to -78 C) under an inert atmosphere. The skilled person will appreciate that the base may need to be added to the compound of formula II before the addition of the compound of formula III. Further, one leaving group may be converted into another leaving group (e.g.
into a stronger/better leaving group in the compound of formula III, for instance by iodide exchange, e.g. by adding an iodide source (e.g. KI) to a compound of formula Ill in which L' is chloro, thereby exchanging the chloride with iodide);
(ii) for compounds of formula I in which the dotted lines are not present and R2 is present and is not H, reaction of a compound of formula I in which the dotted lines are not present and R2 is H with a compound of formula IV, Rea-L2 IV

wherein Rea represents R2 as hereinbefore defined provided that it does not represent H, and L2 represents a suitable leaving group, such as one hereinbefore defined in respect of L', under suitable conditions, such as those hereinbefore described in respect of process step (i);

(iii) for compounds of formula I in which the dotted lines are not present and R2 is H, reduction of a compound of formula I in which the dotted lines represent bonds (so forming double bonds in the compound of formula I) or protected derivatives thereof, for example under standard conditions, such as under hydrogenation reaction conditions (e.g. catalytic hydrogenation conditions in the presence of a precious metal catalyst, e.g.
Pd/C);

(iv) for compounds of formula I in which one or both of the dotted lines represent bonds (so forming one or two double bonds in the compound of formula I), dehydrogenation or oxidation of a compound of formula I in which one or both of the dotted lines are not present and R2 is H, or protected derivatives thereof, for example under standard conditions, such as in the presence of a suitable reagent (e.g. DDQ (2,3-dichloro-5,6-dicyano-l,4-benzoquinone)) and/or by heating in the presence of Pd/C;

(v) for compounds of formula I wherein the dotted lines represent bonds, reaction of a compound of formula V, Yla 0 (R6)M1 V
(R)n R3 \

or a protected derivative thereof, wherein R3, R4 R6 R7 and n are as hereinbefore defined, and ml is 0, 1 or 2 (the skilled person will appreciate that -(R6)m represents two optional R6 substituents, and that the structure of the compound of formula V
dictates that these substituents may only be positioned at the carbonyl carbon and or in the (3 position relative to the carbonyl carbon) and y1a is -OH or -NYaYb, where ya and Yb are independently alkyl (e.g. C,_12 alkyl, including cycloalkyl), heterocycloalkyl, aryl and/or heteroaryl, or Ya and yb may be joined to form a ring optionally containing one or more 3o additional heteroatom, with a compound of formula VI, B TZIANNH VI

or a protected derivative thereof, wherein B1, Tz and A' are as hereinbefore defined, under suitable conditions, for example under acid reaction conditions (e.g. in the presence of a hydrogen halide (e.g. HCl) optionally in a suitable solvent, such as an alcoholic solvent, e.g. ethanol);

(vi) for compounds of formula I where the dotted lines represent bonds, reaction of a compound of formula VII, O

Vi l (R7)n or a protected derivative thereof, wherein R3, R4, R7 and m are as hereinbefore defined, with a compound of formula VI as hereinbefore defined and in the presence of a suitable reagent such as an ester (e.g. C1.6 ester) of formic acid (e.g. methyl or ethyl formate) or a suitable equivalent thereof (e.g. triethyl orthoformate) under conditions known to one skilled in the art, such as standard Aldol-type reaction conditions, conditions such as those hereinbefore defined in respect of process step (v) or, when e.g.
triethyl formate is employed under acidic reaction conditions;

(vii) for compounds of formula I in which the dotted lines do not represent bonds and R2 is H, intramolecular reaction of a compound of formula VIII, O
L3 N'J~ NH Vlll ' ATZ.B
(R7)n or a protected derivative thereof, wherein L3 represents a suitable leaving group as hereinbefore defined in respect of L', and R3, R4, R7 B', Tz, A' and n are as hereinbefore defined, under suitable conditions, such as those hereinbefore described in respect of process step (i);
(viii) for compounds of formula I in which the dotted lines do not represent bonds, reaction of a compound of formula IX, ' NH HNC

(R6)n, IX
(R7)n or a protected derivative thereof, where R1, R3, R4, R6, R7, m and n are as hereinbefore defined, and R2 is present and is as hereinbefore defined, with a compound of formula X, O

where L4 and L5 independently represent a suitable leaving group, such as -O-C,_6 alkyl (e.g. -OEt), a heterocycle (e.g. imidazole) wherein the heterocycle is bound to the carbonyl group at the heteroatom (e.g. 1,1'-carbonyldiimidazole) or a chloro group (e.g.
phosgene, or a suitable phosgene derivative such as triphosgene), optionally in the presence of a suitable base, such as an amine base (e.g. pyridine), for example optionally in the presence of a suitable solvent, such as a polar aprotic solvent (e.g.
toluene, preferably, tetrahydrofuran or diethyl ether);

(ix) for compounds of formula I, reaction of a compound of formula XI, RNAN(R2) Y (R6)m XI
L 5a or a protected derivative thereof, where R', R2 R6, m and the dotted lines are as hereinbefore defined and L5a represents a suitable leaving group, such as one hereinbefore defined in respect of L5, e.g. chloro, bromo, ibdo, a sulfonate group (e.g.
-OS(O)2CF3, -OS(O)2CH3, -OS(O)2PhMe or a nonaflate), -B(OH)2, -B(ORwX)2, -Sn(R")3, diazonium salts, or a similar group known to the skilled person (in which each RWX
independently represents a C1-6 alkyl group, or, in the case of -B(OR"'X)2, the respective R'"X groups may be linked together to form a 4- to 6-membered cyclic group (such as a 4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl group)), and L5a preferably represents -B(OH)2, with a compound of formula XII, (R7)n XII

or a protected derivative thereof, where R3, R4, R7 and n are as hereinbefore defined, and L6 represents a suitable leaving group such as chloro, bromo, iodo, a sulfonate group (e.g. -OS(O)2CF3, -OS(O)2CH3, -OS(O)2PhMe or a nonaflate), -B(OH)2, -B(OR"'X)2, -Sn(R"'X)3 or diazonium salts, in which each RWX independently represents a C1_6 alkyl group, or, in the case of -B(OR')2, the respective Rv" groups may be linked together to form a 4- to 6-membered cyclic group (such as a 4,4,5,5-tetramethyl-1,3,2-dioxaboroian-2-yl group), and L6 preferably represents bromo (the skilled person will also appreciate that L5 and L6 should be mutually compatible, and may also be interchanged), for example, in the presence of a suitable catalyst system, e.g. a metal (or a salt or complex thereof) such as Cul, Pd/C, PdCI2, Pd(OAc)2, Pd(Ph3P)2CI2, Pd(Ph3P)4, Pd2(dba)3 or NiCl2 and a ligand such as t-Bu3P, (C6Hõ)3P, Ph3P, AsPh3, P(o-Tol)3, 1,2-bis(diphenylphosphino)ethane, 2,2'-bis(di-tert-butylphosphino)-1,1'-biphenyl, 2,2'-bis(diphenylphosphino)-1, 1'-bi-naphthyl, 1,1'-bis(diphenylphosphinoferrocene), 1,3-bis(di phenyl-phosphino) propane, xantphos, or a mixture thereof, together with a suitable base such as, Na2CO3, K3P04, Cs2CO3, NaOH, KOH, K2CO3, CsF, Et3N, (i-Pr)2NEt, t-BuONa or t-BuOK (or mixtures thereof) in a suitable solvent such as dioxane, toluene, ethanol, dimethylformamide, ethylene glycol dimethyl ether, water, dimethylsulfoxide, acetonitrile, dimethylacetamide, N-methylpyrrolidinone, tetrahydrofuran or mixtures thereof. The reaction may also be carried out for example at room temperature or above (e.g. at a high temperature such as the reflux temperature of the solvent system) or using microwave irradiation;

(x) compounds of formula I, particularly those in which R3 represents -OR4a in which R4a is other than hydrogen, reaction of a compound of formula XIII, O
RNAN(R2) (R6)m XIII
(R)n L
or a protected derivative thereof, wherein R', R2, R6, R7, m, n and the dotted lines are as hereinbefore defined and L7 represents Lx or R3 as hereinbefore defined, and represents Lx or -OR4 as hereinbefore defined, and Lx represents a suitable leaving group such as chloro, bromo, iodo, a sulfonate group (e.g. -OS(O)2CF3, -OS(O)2CH3, -OS(O)2PhMe or a nonaflate), -B(OH)2, -B(OR")2, -Sn(R")3 or diazonium salts, in which each R" independently represents a C1.6 alkyl group with a compound of formula XIV, R4x-OH XIV

wherein R4x represents R4 or R4a as required/appropriate, under suitable conditions, for example optionally in the presence of an appropriate metal catalyst (or a salt or complex thereof) such as Cu, Cu(OAc)2, Cul (or Cul/diamine complex), copper tris(triphenyl-phosphine)bromide, Pd(OAc)2, Pd2(dba)3 or NiCl2 and an optional additive such as Ph3P, 2,2'-bis(diphenylphosphino)-1,1'-binaphthyl, xantphos, Nal or an appropriate crown ether such as 18-crown-6-benzene, in the presence of an appropriate base such as NaH, Et3N, pyridine, N,N'-dimethylethylenediamine, Na2CO3, K2CO3, K3PO4, Cs2CO3, t-BuONa or t-BuOK (or a mixture thereof, optionally in the presence of 4A molecular sieves), in a suitable solvent (e.g. dichloromethane, dioxane, toluene, ethanol, isopropanol, dimethylformamide, ethylene glycol, ethylene glycol dimethyl ether, water, dimethylsulfoxide, acetonitrile, dimethylacetamide, N-methylpyrrolidinone, tetrahydrofuran or a mixture thereof) or in the absence of an additional solvent when the reagent may itself act as a solvent (e.g. when -R 4x represents R4 and R4 represents methyl). This reaction may be carried out at room temperature or above (e.g.
at a high temperature, such as the reflux temperature of the solvent system that is employed) or using microwave irradiation;

(xi) for compounds of formula I in which R3 represents -OR 4a in which-R41 is other than hydrogen and/or where R4 is other than hydrogen, reaction of a corresponding compound of formula I in which R3 represents -OH and/or R4 represents hydrogen, with a compound of formula XV, wherein R4Y represents R4 or R4a as required/appropriate, and L9 represents a suitable leaving group such as one defined hereinbefore in respect of L1, under suitable reaction conditions, for example such as those hereinbefore described in respect of process step (i);

(xii) for compounds of formula I in which TZ represents -N(R"r1)-, reaction of a compound of formula XVI, O
IN N_(R

(R6)m XVI
(R7n or a protected derivative thereof, wherein L10 represents a suitable leaving group, such as one hereinbefore defined in respect of L1 and R2, R3, R4, R6, R7, m, n and the dotted lines are as hereinbefore defined, with a compound of formula XVII, H-Za XVI l wherein Za represents -N(R")-B', and R"'' and B' are as hereinbefore defined, under suitable conditions, for example those hereinbefore described in respect of process step (i);

(xiii) for compounds of formula I in which Tz represents -C(O)-N(Rw2)-, reaction of a compound of formula XVIII, HO O
T O
A1NN,(R2) (R6)m XVII I
(R) n or a protected derivative thereof (e.g. an ester derivative), wherein the dotted lines, R2, R3, R4, R5, R6, R7, A', m, n and the dotted lines are as hereinbefore defined, with a compound of formula XIX, H-Zb XIX

wherein Zb represents -N(Rw2)-B', and R"'2 and B1 are as hereinbefore defined, under standard amide coupling reaction conditions, for example in the presence of a suitable coupling reagent (e.g. 1,1'-carbonyldiimidazole, N,N'-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (or hydrochloride thereof), N,N'-disuccinimidyl carbonate, benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate, 2-(1 H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, benzotriazol-1-yloxytris-pyrrolidinophosphonium hexafluorophosphate, bromo-tris-pyrrolidinophosponium hexafluorophosphate, 2-(1 H-benzotriazol-1 -yl)-1, 1,3,3-tetramethyluronium tetra-fluorocarbonate, 1-cyclohexyl-carbodiimide-3-propyloxymethyl polystyrene, O-(7-azabenzotriazol-1-yl)-N,N,N,N tetramethyluronium hexafluorophosphate and/or O-benzotriazol-1-yl-N, N, N',N'-tetramethyluronium tetrafluoroborate), optionally in the presence of a suitable base (e.g. sodium hydride, sodium bicarbonate, potassium carbonate, pyridine, triethylamine, dimethylaminopyridine, diisopropylamine, sodium hydroxide, potassium tert-butoxide and/or lithium diisopropylamide (or variants thereof), an appropriate solvent (e.g.
tetrahydrofuran, pyridine, toluene, dichloromethane, chloroform, acetonitrile, dimethylformamide, trifIuoromethylbenzene, dioxane or triethylamine) and a further additive (e.g. 1-hydroxybenzotriazole hydrate). Alternatively, the carboxylic acid group of the compound of formula XVIII may be converted under standard conditions to the corresponding acyl chloride (e.g. in the presence of SOCI2 or oxalyl chloride), which acyl chloride is then reacted with a compound of formula XIX, for example under similar conditions to those mentioned above.

Compounds of formula If wherein the dotted lines represent bonds may be prepared by reaction of a compound of formula V, preferably wherein Y' represents -OH, with urea under conditions hereinbefore described in respect of process step (v).
Compounds of formula V in which Y' represents -OH may be prepared by hydrolysis of a compound of formula V wherein Y' represents -NYaYb, under conditions known to those skilled in the art, for example in the presence of an aqueous base (e.g.
aqueous NaOH) and optionally in the presence of a suitable solvent or solvent mixture (e.g.
ethanol and water).

Compounds of formula V in which Y' represents -OH may also be prepared by reaction of a compound of formula VII with a suitable ester of formic acid (e.g.methyl or ethyl formate) or the like, for example under reaction conditions known to those skilled in the art, such as those hereinbefore described in respect of preparation of compounds of formula I (process step (v)).

Compounds of formula V, in which Y' represents -NYaYb, wherein Ya and yb are both methyl, may be prepared by reaction of a compound of formula VII with DMF
(which, the skilled person will understand, may also be used as a solvent or co-solvent), under conditions known to those skilled in the art, for example in the presence of POC13 and optionally in the presence of a suitable solvent or solvent mixture.

Compounds of formula VI may be prepared by reaction of urea with a compound of formula III under conditions known to those skilled in the art, for example those described hereinbefore in respect of process step (i).

I Compounds of formula Vlll wherein L3 represents an iodo, chloro or, preferably, a bromo group, may be prepared by reaction of a compound of formula XX, O
HO N)~ NH XX
H
A TZ.B
R7)n R3 \

wherein R3, R4, R5, R7, A', Tz, B1 and n are as hereinbefore defined, with a suitable halogenating agent, for example, where L3 represents a bromo group, reaction with CBr4 and PPh3 in the presence of a suitable solvent (e.g. dichioromethane).

Compounds of formula Vill wherein L3 represents a sulfonate group may be prepared by reaction of a compound of formula XX as hereinbefore defined, or a suitable protected derivative thereof, with a suitable sulfonyl chloride, for example trifluoromethane sulfonylchloride or p-toluene sulfonylchloride, optionally in the presence of a suitable amine base (e.g. pyridine or triethyl amine) and in the presence of a suitable solvent (e.g.
dichloromethane).
Compounds of formula XVIII may be prepared by reaction of a compound of formula II as hereinbefore defined, with a compound of formula XXI, L"-A'-C(O)OH XXI
or a protected derivative (e.g. ester) thereof, wherein L" represents a suitable leaving group, for example one hereinbefore defined in respect of L' (e.g. bromo) and A' is as hereinbefore defined, under standard reaction conditions known to those skilled in the art, for example such as those hereinbefore defined in respect of preparation of compounds of formula I (process step (i) above).

Compounds of formula XX may be prepared by reaction of a compound of formula XXII, (R), or a protected derivative thereof, with a compound of formula XXIII, B'-TZ

A'-N=C=O XXIII

wherein R3, R4, R7, A', Tz, B' and n are as hereinbefore defined, optionally in the presence of a suitable solvent (e.g. tetrahydrofuran) and under conditions known to one skilled in the art.
Compounds of formula XXII may be prepared by reduction of a compound of formula XXIV, R)n R3 \

wherein R3, R4, R7 and n are as hereinbefore described, under conditions known to one skilled in the art, for example by reaction with a suitable reagent, for example a suitable reagent (e.g. triphenylphosphine), optionally in presence of a suitable solvent (e.g. THF).
Compounds of formula XXIV may be prepared by reaction of a compound of formula XXV, ;5 H O O H XXV

R7) or a suitably protected derivative thereof (e.g. a mono 0-protected derivative), wherein R3, R4, R' and n are as hereinbefore defined, with A a suitable sulfonating agent (e.g. p-toluenesulfonyl chloride), under conditions known to one skilled in the art, for example in the presence of a suitable base (e.g. pyridine), a suitable catalyst (e.g. DMAP) and a suitable solvent (e.g.
THE or DCM); followed by B a suitable source of an azide nucleophile, for example an azide salt (e.g.
sodium azide), under conditions known to one skilled in the art, for example in the presence of a suitable solvent (e.g. DMF) and optionally in the presence of a suitable metal ion complexing agent, for example a crown ether (e.g. 15-crown-5).
Compounds of formula XXV may be prepared by reduction of:
(a) a compound of formula XXVI, HO OH XXVI
(R), R3 \

OR4 ; or (b) a compound of formula XXVIA, HO OH XXVIA
(R), or a suitably protected derivative thereof (e.g. ester), wherein, in both cases, R3, R4, R7 and n are as hereinbefore defined, under conditions known to one skilled in the art, for example in the presence of a suitable reducing agent, such as a suitable borane or complex thereof (e.g. BH3=THF) and in the presence of a suitable solvent (e.g.
THF).
Compounds of formula XXII may also be obtained by reaction of a compound of formula XXVI as hereinbefore defined, or preferably a suitably protected derivative thereof, for example, an ester derivative (e.g. a methyl ester), with:

A a suitable sulfonating agent (e.g. p-toluenesulfonyl chloride, so forming a tosylate group; alternatively, the skilled person will appreciate that corresponding compounds in which the tosylate group is replaced with a different leaving group, such as chloro, bromo or iodo, may also be employed), under conditions known to one skilled in the art, for example in the presence of a suitable base (e.g.
pyridine), a suitable catalyst (e.g. DMAP) and a suitable solvent (e.g. THE or DCM); followed by B a suitable source of an azide nucleophile, for example an azide salt (e.g.
sodium azide), under conditions known to one skilled in the art, for example in the presence of a suitable solvent (e.g. DMF) and optionally in the presence of a suitable metal ion complexing agent, for example a crown ether (e.g. 15-crown-5); followed by C a suitable reducing agent (e.g. lithium aluminum hydride (LiAIH4)), under conditions known to one skilled in the art, for example in the presence of a suitable solvent (e.g. tetrahydrofuran).

Suitably protected derivatives (e.g. O-benzylated derivatives) of compounds of formula XXVI may be prepared by reaction of a compound of formula XXVII, U XXVII
3 (R7), R

wherein U represents -ORu or -N(Ru')Ru2, in which Ru, Ru' and RU2 independently represent hydrogen, C1.12 alkyl or aryl (which latter two groups may be optionally substituted by one or more substituents selected from a substituent such as one hereinbefore defined by X' and, in the case of C1_12 alkyl, =0), or, Ru' and R
U2 may be linked together to form an optionally substituted (e.g. by one or more substituents selected from a substituent such as one hereinbefore defined by X1, aryl and heteroaryl), and R3, R4, R7 and n are as hereinbefore defined. Preferably Ru' and R U2 do not represent hydrogen. When Ru' and R U2 are linked together, they may together form the following group (i.e. U may represent the following group):

N
or an enantiomer thereof (or another suitable chiral derivative thereof, such as one based on Evans' chiral auxiliary), with formaldehyde, paraformaldehyde or a suitably protected derivative (e.g. an O-benzylated derivative) of a compound of formula XXVIII, or a derivative thereof, under suitable conditions known to one skilled in the art, for example those hereinbefore defined in respect of process step (i), followed by hydrolysis under suitable conditions as known to one skilled in the art, for example in the presence of an aqueous base such as sodium hydroxide.

Compounds of formula XXVIA may be prepared by reaction of a compound of formula XXVII (as hereinbefore defined) or a compound of formula XXIX (as defined hereinafter) with a compound of formula XXVIIIA, HO-C(O)-Cl XXVIIIA

for example under reaction conditions known to those skilled in the art, such as those hereinbefore described in respect of preparation of compounds of formula XXVI.

Alternatively, compounds of formula XXVIA may be prepared by reaction of a compound corresponding to a compound of formula Xll but in which L6 represents a metal-containing group, such as Li, MgBr, ZnCI or the like (which may be prepared by reaction of a corresponding compound of formula XII in which L6 represents halo, by e.g.
Iithiation, a Grignard-forming reaction, followed by, if necessary, metal-exchange reactions and the like) with a compound of formula XXVIIIB, HO-C(O)-C(H)(W")-C(O)OH XXVIIIB
wherein W" represents a suitable leaving group, such as chioro (or the like), for example under reaction conditions known to those skilled in the art, e.g. such as those catalytic reaction conditions described in respect of preparation of compounds of formula I
(process step (ix)).

Compounds of formula XXVII may be prepared by reaction of a compound of formula XXIX, O
HOH XXIX
r (R7~n R3 ~

wherein R3, R4, R7 and n are as hereinbefore defined, with a compound of formula XXX, H
N O
XXX
under suitable conditions known to one skilled in the art, such as those hereinbefore described in respect of process step (xiii).

Compounds of formulae IV, VII, X, XI, XII, XIII, XV, XVI, XXVIIIA, XXVIIIB, XXIX and XXX (and also others, e.g. certain compounds of formulae VI and IX) may be commercially available, are known in the literature, or may be obtained either by analogy with the processes described herein, or by conventional synthetic procedures, in accordance with standard techniques, from.available starting materials using appropriate reagents and reaction conditions. In this respect, the skilled person may refer to inter alia "Comprehensive Organic Synthesis" by B. M. Trost and I. Fleming, Pergamon Press, 1991.

The substituents either in final compounds of the invention or in relevant intermediates (as appropriate) may be modified one or more times, after or during the processes described above by way of methods that are well known to those skilled in the art.
Examples of such methods include substitutions, reductions, oxidations, alkylations, acylations, hydrolyses, esterifications, etherifications, halogenations or nitrations. Such reactions may result in the formation of a symmetric or asymmetric final compound of the invention or intermediate. In this respect, the skilled person may also refer to "Comprehensive Organic Functional Group Transformations" by A. R. Katritzky, O. Meth-Cohn and C. W. Rees, Pergamon Press, 1995. Specific transformation steps that may be mentioned include the conversion of one L6 group (in the compound of formula XII) into another L6 group (e.g. the conversion of one halo group, such as chloro, into another halo group, such as iodo, for example by reaction in the presence of potassium iodide), or even the conversion of a hydroxy group to a boronic acid group. Other transformation steps include the reduction of a nitro group to an amino group, the hydrolysis of a nitrile group to a carboxylic acid group, and standard nucleophilic aromatic substitution reactions.
As stated herein, the skilled person will also appreciate that chiral groups may be employed in order to obtain optically active compounds of the invention or intermediates thereof. For example, optically active compounds of formula XXVII may be employed (e.g. a variant based on Evan's chiral auxiliary).

It will also be appreciated by those skilled in the art that in the process described below the functional groups of intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (e.g., t-butyldimethylsilyl, t-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, methyl and the like. Suitable protecting groups for amino, amidino and guanidino include t-butoxycarbonyl, benzyloxycarbonyl, and the like.
Suitable protecting groups for mercapto include -C(O)-R" (where R" is alkyl, aryl or aralkyl), p-methoxybenzyl, trityl and the like. Suitable protecting groups for carboxylic acid include alkyl, aryl or aralkyl esters. Further, a carbonyl group may be protected as the silyl enol ether, which may be introduced under standard conditions, and converted back to the enolate (or carbonyl compound) by reaction in the presence of fluoride ions (or a suitable source thereof).
Protecting groups may be added or removed in accordance with standard techniques (for example a methyl protecting group on a hydroxy group may be removed by reaction in the presence of a suitable 'cleaving reagent' such as BBr3), which, are known to one skilled in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P.G.M. Wuts, Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley.

The protecting group may also be a polymer resin such as a Wang resin or a 2-chlorotrityl-chloride resin.

Medical and Pharmaceutical Uses Compounds of the invention are indicated as pharmaceuticals. According to a further aspect of the invention there is provided a compound of the invention, as hereinbefore 3o defined, for use as a pharmaceutical.

Although compounds of the invention may possess pharmacological activity as such, certain pharmaceutically-acceptable (e.g. "protected") derivatives of compounds of the invention may exist or be prepared which may not possess such activity, but may be administered parenterally or orally and thereafter be metabolised in the body to form compounds of the invention. Such compounds (which may possess some pharmacological activity, provided that such activity is appreciably lower than that of the "active" compounds to which they are metabolised) may therefore be described as "prodrugs" of compounds of the invention.

By "prodrug of a compound of the invention", we include compounds that form a compound of the invention, in an experimentally-detectable amount, within a predetermined time (e.g. about 1 hour), following oral or parenteral administration. All prodrugs of the compounds of the invention are included within the scope of the invention.

Furthermore, certain compounds of the invention may possess no or minimal pharmacological activity as such, but may be administered parenterally or orally, and thereafter be metabolised in the body to form compounds (e.g. compounds of the invention) that possess pharmacological activity as such. Such compounds (which also includes compounds that may possess some pharmacological activity, but that activity is appreciably lower than that of the "active" compounds of the invention to which they are metabolised), may also be described as "prodrugs".

Thus, the compounds of the invention are useful because they possess pharmacological activity, and/or are metabolised in the body following oral or parenteral administration to form compounds which possess pharmacological activity.

According to a further aspect of the invention there is provided a pharmaceutical composition/formulation including a compound of the invention as hereinbefore defined in admixture with a pharmaceutically acceptable adjuvant, carrier, diluent or excipient.
Depending on e.g. potency and physical characteristics of the compound of the invention (i.e. active ingredient), pharmaceutical formulations that may be mentioned include those in which the active ingredient is present in at least 1 % (or at least 10%, at least 30% or at least 50%) by weight. That is, the ratio of active ingredient to the other components (i.e.
the addition of adjuvant, diluent and carrier) of the pharmaceutical composition is at least 1:99 (or at least 10:90, at least 30:70 or at least 50:50) by weight.

Such compositions/formulations may be prepared in accordance with standard and/or accepted pharmaceutical practice.

Compounds of the invention will normally be administered orally, intravenously, subcutaneously, buccally, rectally, dermally, nasally, tracheally, bronchially, sublingually, by any other parenteral route or via inhalation, in a pharmaceutically acceptable dosage form.
Compounds of the invention may be administered alone, but are preferably administered by way of known pharmaceutical formulations, including tablets, capsules or elixirs for oral administration, suppositories for rectal administration, sterile solutions or suspensions for parenteral or intramuscular administration, and the like.
The invention further provides a process for the preparation of a pharmaceutical composition/formulation, as hereinbefore defined, which process comprises bringing into association a compound of the invention, as hereinbefore defined, or a pharmaceutically acceptable derivative (e.g. salt) thereof, with a pharmaceutically-acceptable adjuvant, carrier, diluent or excipient.

Compounds of the invention may be useful as inhibitors of certain enzymes such as a cyclic AMP phosphodiesterase, a phosphodiesterase 7; a phosphodiesterase 4; a phosphodiesterase 3; or a cyclic GMP phosphodiesterase. In particular, compounds of the invention may be useful as inhibitors of a phosphodiesterase 7 and, particularly, a phosphodiesterase 4.

Accordingly, compounds of the invention may therefore be useful in treating or preventing inflammatory diseases or conditions in a patient. Hence, in another aspect, this invention is directed to methods for treating or preventing an inflammatory disease or condition in a mammal, preferably a human, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention as hereinbefore described.

3o The term "inflammation" will be understood by those skilled in the art to include any condition characterised by a localised or a systemic protective response, which may be elicited by physical trauma, infection, chronic diseases, such as those mentioned hereinbefore, and/or chemical and/or physiological reactions to external stimuli (e.g. as part of an allergic response). Any such response, which may serve to destroy, dilute or sequester both the injurious agent and the injured tissue, may be manifest by, for example, heat, swelling, pain, redness, dilation of blood vessels and/or increased blood flow, invasion of the affected area by white blood cells, loss of function and/or any other symptoms known to be associated with inflammatory conditions.

The term "inflammation" will thus also be understood to include any inflammatory disease, disorder or condition per se, any condition that has an inflammatory component associated with it, and/or any condition characterised by inflammation as a symptom, including inter alia acute, chronic, ulcerative, specific, allergic and necrotic inflammation, and other forms of inflammation known to those skilled in the art. The term thus also includes, for the purposes of this invention, inflammatory pain and pain generally.
Where a condition has an inflammatory component associated with it, or a condition characterised by inflammation as a symptom, the skilled person will appreciate that compounds of the invention may be useful in the treatment of the inflammatory symptoms and/or the inflammation associated with the condition.
The inflammatory condition or disease may be an autoimmune condition or disease; the inflammatory condition or disease may involve acute or chronic inflammation of bone and/or cartilage compartments of joints; the inflammatory condition or disease may be an arthritis selected from rheumatoid arthritis, gouty arthritis or juvenile rheumatoid arthritis;
the inflammatory condition or disease may be a respiratory disorder selected from asthma or a chronic obstructive pulmonary disease (COPD, e.g., emphysema or chronic bronchitis); the condition or disease may be associated with the disregulation of T-cells;
the condition or disease may be associated with elevated levels of inflammatory cytokines (e.g., wherein the inflammatory cytokine is IL-2, or wherein the inflammatory cytokine is IFN-y, or wherein the inflammatory cytokine is TNF-a); the inflammatory condition or disease may be multiple sclerosis; the inflammatory condition or disease may be pulmonary sarcadosis.; the inflammatory condition or disease may be ocular inflammation or allergy; the inflammatory condition or disease may be an inflammatory bowel disease (e.g., Crohn's disease or ulcerative colitis); and the inflammatory condition or disease may be an inflammatory cutaneous disease (e.g., psoriasis or dermatitis).

Compounds of the invention may be useful in modulating intracellular cyclic adenosine 5'-monophosphate levels within a mammal, preferably a human. Hence, in another aspect, this invention is directed to methods for modulating intracellular cyclic adenosine 5'-monophosphate levels within a mammal, preferably a human, wherein the method comprises administering to the mammal in need thereof an amount of a compound of the invention (e.g. those hereinbefore defined) or a pharmaceutical formulation/composition of the invention as hereinbefore described effective to modulate the intracellular cyclic adenosine 5'-monophosphate levels of the mammal. The mammal, preferably a human, may have an inflammatory condition or disease (for example one defined herein).

Compounds of the invention may be useful in treating or preventing a disease or condition in a mammal, preferably a human, where the disease or condition is associated with pathological conditions that are modulated by inhibiting enzymes associated with secondary cellular messengers. Hence, in another aspect, this invention is directed to methods for treating or preventing a disease or condition in a mammal, preferably a human, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount of a compound of the invention or a pharmaceutical formulation/composition of the invention as hereinbefore described, and the disease or condition is associated with pathological conditions that are modulated by inhibiting enzymes associated with secondary cellular messengers. Such enzymes (that may be inhibited) may be a cyclic AMP phosphodiesterase; a phosphodiesterase 7; a phosphodiesterase 4; a phosphodiesterase 3; or a cyclic GMP phosphodiesterase.
Further, more than one type of enzyme may be inhibited, for instance, the enzymes may be both phosphodiesterase 4 and phosphodiesterase 3. In particular, the enzyme that may be inhibited is a phosphodiesterase 7 or, preferably, a phosphodiesterase 4.
Compounds of the invention may be useful in treating or preventing uncontrolled cellular proliferation in a mammal, preferably a human. Hence, in another aspect, this invention is directed to methods for treating or preventing uncontrolled cellular proliferation in a mammal, preferably a human, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount (e.g. an amount effective to treat or prevent uncontrolled cellular) of a compound of the invention or a pharmaceutical formulation/composition of the invention as hereinbefore described. The uncontrolled cellular proliferation may be caused by a cancer selected from leukaemia and solid tumors.
Compounds of the invention may be useful in treating or preventing transplant rejection in a mammal, preferably a human. Hence, in another aspect, this invention is directed to methods for treating or preventing transplant rejection in a mammal, preferably a human, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount (e.g. an amount effective to treat or prevent transplant rejection in the mammal) of a compound of the invention. The rejection may be due to graft versus host disease.

Compounds of the invention may be useful in treating or preventing conditions associated with the central nervous system (CNS) in a mammal, preferably a human.
Hence, in another aspect, this invention is directed to methods for treating or preventing conditions associated with the central nervous system in a mammal, preferably a human, wherein the method comprises administering to the mammal in need thereof a therapeutically effective amount (e.g. an amount effective to treat or prevent conditions associated with the central nervous system (CNS) in the mammal) of a compound of the invention as described above (e.g. those hereinbefore defined) or a pharmaceutical formulation/composition of the invention as hereinbefore described. The condition associated with the central nervous system (CNS) may be depression.

These and other aspects and embodiments of the present invention will be apparent upon reference to the following detailed description. To this end, various references are set forth herein which describe in more detail certain procedures, compounds and/or formulations/compositions, and are hereby incorporated by reference in their entirety.
In particular, compounds of the invention are inhibitors of PDE7 and, preferably, PDE4.
As used herein, the terms "disease" and "condition" may be used interchangeably or may be different in that the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognised as a disease but only as an undesirable condition or syndrome, wherein a more-or-less specific set of symptoms have been identified by clinicians.
Thus, the compounds and compositions of the invention may be used to treat inflammation, including both acute and chronic inflammation as well as certain proliferative disorders (cancers). As used herein, inflammation includes, without limitation, ankylosing spondylitis, arthritis (e.g. juvenile arthritis and rheumatoid arthritis), asthma, COPD, chronic bronchitis, respiratory distress syndrome, rhinitis, allergic rhinitis, Crohn's disease, nephritis, eczema, dermatitis (e.g. atopic dermatitis), urticaria, conjunctivitis, ulcerative colitis, rheumatoid arthritis, osteoarthritis, eosinophilic gastrointestinal disorders, vascular disease, diabetes mellitus, fibromyalgia syndrome, gout, inflammations of the brain (including multiple sclerosis, AIDS dementia, Lyme encephalopathy, herpes encephalitis, Creutzfeld-Jakob disease, and cerebral toxoplasmosis), emphysema, inflammatory bowel disease, irritable bowel syndrome, ischemia-reperfusion injury juvenile erythematosus pulmonary sarcoidosis, Kawasaki disease, osteoarthritis, pelvic inflammatory disease, psoriatic arthritis, psoriasis, tissue/organ transplant, scleroderma, spondyloarthropathies, systemic lupus erythematosus, pulmonary sarcoidosis, ulcerative colitis, viral infections (i.e.
inflammation associated with a viral infection) (e.g. influenza, common cold, herpes zoster, hepatitis C and AIDS), bacterial infections (i.e. inflammation associated with a bacterial infection), and any other disease with an inflammatory component. As used herein, proliferative disorders includes, without limitation, all cancers, leukemias and solid tumors that are susceptible to undergoing differentiation or apoptosis upon interruption of their cell cycle. As stated herein, the compounds and compositions of the invention may also be useful for treating diseases associated with the central nervous system. Such diseases include cognitive function, Alzheimer's disease and other neurodegenerative disorders, learning and memory disorders.

Compounds of the invention may inhibit disease induction, for example in the models in the biological examples, at doses of less than 500 mg/kg. The Biological Examples below outline some, but not all, of the preclinical models that may be used to support the claims of this patent. For instance, compounds of the examples are tested in the Biological Example 1, and are found to exhibit at least 50% inhibition of PDE4 at a concentration of 10 pM or below (and more preferably at a concentration of 0.3 M or below).

Compounds of the invention may also be combined with other therapeutic agents that are useful in the treatment of the conditions described herein. For instance, the compounds of the invention may be combined with other compounds that may be useful in the treatment of:
i) an inflammatory disorder;
ii) a disorder in which the modulation of intracellular cyclic adenosine 5'-monophosphate levels within a mammal is desired and/or required, which disorder may be an inflammatory disorder;
iii) a disorder associated with pathological conditions that are modulated by inhibiting enzymes associated with secondary cellular messengers (e.g. a cyclic AMP
phosphodiesterase; a phosphodiesterase 4; a phosphodiesterase 3; a cyclic GMP
phosphodiesterase; or both phosphodiesterase 4 and phosphodiesterase 3), which disorder may be an inflammatory disorder (it is most preferred that compounds of the invention are combined (an) inhibitor(s) of PDE7 or, in particular, (an) inhibitor(s) of PDE4);
iv) transplant rejection in a mammal;

v) uncontrolled cellular proliferation; and/or vi) a disorder associated with the central nervous system.

According to a further aspect of the invention, there is provided a combination product comprising:
(A) a compound of the invention as hereinbefore defined; and (B) another therapeutic agent that is useful in the treatment of i), ii), iii), iv), v) or vi) above (e.g. a therapeutic agent that is useful in the treatment of an inflammatory disorder), wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient.

Such combination products provide for the administration of a compound of the invention in conjunction with the other therapeutic agent, and may thus be presented either as separate formulations, wherein at least one of those formulations comprises a compound of the invention, and at least one comprises the other therapeutic agent, or may be presented (i.e. formulated) as a combined preparation (i.e. presented as a single formulation including a compound of the invention and the other therapeutic agent).

Thus, there is further provided:

(1) a pharmaceutical formulation/composition including a compound of the invention, as hereinbefore defined, another therapeutic agent that is useful in the treatment of i), ii), iii), iv), v) or vi) above (e.g. a therapeutic agent that is useful in the treatment of an inflammatory disorder), and a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient; and (2) a kit of parts comprising components:
(a) a pharmaceutical formulation/composition including a. compound of the invention, as hereinbefore defined, in admixture with a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient; and (b) a pharmaceutical formulation/composition including another therapeutic agent that is useful in the treatment of i), ii), iii), iv), v) or vi) above (e.g. a therapeutic agent that is useful in the treatment of an inflammatory disorder) in admixture with a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.

The invention further provides a process for the preparation of a combination product as hereinbefore defined, which process comprises bringing into association a compound of the invention, as hereinbefore defined, or a pharmaceutically acceptable derivative (e.g.
salt) thereof with another therapeutic agent that is useful in the treatment of i), ii), iii), iv), v) or vi) above (e.g. a therapeutic agent that is useful in the treatment of an inflammatory disorder), and at least one pharmaceutically-acceptable adjuvant, diluent, carrier or excipient.

By "bringing into association", we mean that the two components are rendered suitable for administration in conjunction with each other.

Thus, in relation to the process for the preparation of a kit of parts as hereinbefore defined, by bringing the two components "into association with" each other, we include that the two components of the kit of parts may be:
(i) provided as separate formulations (i.e. independently of one another), which are subsequently brought together for use in conjunction with each other in combination therapy; or (ii) packaged and presented together as separate components of a "combination pack"
for use in conjunction with each other in combination therapy.

The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed;
the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disease or condition; and the subject undergoing therapy.

The term "effective amount" refers to an amount of a compound, which confers a therapeutic effect on the treated. patient. The effect may be objective (i.e.
measurable by some test or marker) or subjective (i.e. the subject gives an indication of or feels an effect).

Compounds of the invention may be administered at varying doses. Oral, pulmonary and topical dosages may range from between about 0.01 mg/kg of body weight per day (mg/kg/day) to about 100 mg/kg/day, preferably about 0.01 to about 10 mg/kg/day, and more preferably about 0.1 to about 5.0 mg/kg/day. For e.g. oral administration, the compositions typically contain between about 0.01 mg to about 500 mg, and preferably between about 1 mg to about 100 mg, of the active ingredient. Intravenously, the most preferred doses will range from about 0.001 to about 10 mg/kg/hour during constant rate infusion. Advantageously, compounds may be administered in a single daily dose, or the total daily dosage may be administered in divided doses of two, three or four times daily.
When a pharmaceutical composition containing a compound of the invention is employed, it shall contain an appropriate amount/concentration/ratio of the active ingredient.

The ranges of effective doses provided herein are not intended to be limiting and represent preferred dose ranges. However, the most preferred dosage will be tailored to the individual subject, as is understood and determinable by one skilled in the relevant arts. (see, e.g., Berkow et al., eds., The Merck Manual, 16th edition, Merck and Co., Rahway, N.J., 1992; Goodmanetna., eds.,Goodman and Cilman's The Pharmacological Basis of Therapeutics, 10th edition, Pergamon Press, Inc., Elmsford, N.Y., (2001);
Avery's Drug Treatment: Principles and Practice of Clinical Pharmacology and Therapeutics, 3rd edition, ADIS Press, LTD., Williams and Wilkins, Baltimore, MD.
(1987), Ebadi, Pharmacology, Little, Brown and Co., Boston, (1985); Osolci al., eds., Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Co., Easton, PA
(1990); Katzung, Basic and Clinical Pharmacology, Appleton and Lange, Norwalk, CT
(1992)).

The physician, or the skilled person, will be able to determine the actual dosage and/or route of administration which will be most suitable for an individual patient, which is likely to vary with the route of administration, the type and severity of the condition that is to be treated, as well as the species, age, weight, sex, renal function, hepatic function and 3o response of the particular patient to be treated. The above-mentioned dosages are exemplary of the average case; there can, of course, be individual instances where higher or lower dosage ranges are merited, and such are within the scope of this invention.

Compounds of the invention may have the advantage that they are effective inhibitors (and hence particularly effective in the treatment of the conditions described herein), and in particular effective PDE inhibitors (such as PDE7 inhibitors and especially effective PDE4 inhibitors).

Compounds of the invention may also have the advantage that they may be more efficacious than, be less toxic than, be longer acting than, be more potent than, produce fewer side effects than, be more easily absorbed than, and/or have a better pharmacokinetic profile (e.g. higher oral bioavailability and/or lower clearance) than, and/or have other useful pharmacological, physical, or chemical properties over, compounds known in the prior art, whether for use in the above-stated indications or otherwise.

Biological Examples In vitro Inhibition of PDE4 phosphodiesterases PDE4 U937 cytoplasmic extracts are prepared by a modified procedure of the assay described in MacKenzie, S.J. and Houslay, M.D., "Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells", Biochem J. (2000), 347(Pt 2):571-8, by lysis of U937 cells (ATCC: Catalogue No. CRL-159) in M-PER Lysis buffer (Pierce) containing 10%
protease inhibitor cocktail (Sigma). The cell lysates are then centrifuged at 30,000 rpm for 15 minutes at 4 C. The supernatants are aliquoted and stored at -80 C.
PDE4 has been shown to be the predominant cyclic nucleotide phosphodieterase activity in U937 cells.

An alternative source of PDE4 enzymes is from recombinant human PDE4 obtained from baculovirus-SF9 cells expression system. cDNA containing PDE4D1 is cloned into a baculovirus vector, insect cells (SF9) are then infected and cells cultured to express the PDE4 protein. The cells are lysed and used directly in assay or partially purified using standard procedures. The process can be used for other PDE4 and PDE enzymes.
Compounds of the invention are evaluated for inhibitory activity against PDE4 enzymes by the following assay Method A or B.
Method A:
PDE4 assay based on modified procedure of Phosphodiesterase [3H]cAMP SPA
Enzyme ;i Assay (Amersham Biosciences, code TRKQ 7090). In this assay, PDE4 enzymes converts [3H]cAMP to [3H]5'-AMP. The assay is quenched by the addition of SPA
yttrium silicate beads which preferentially bind linear nucleotides over cyclic nucleotides in the presence of zinc sulphate. The amount of [3H]5'-AMP formed is proportional to the PDE4 activity, hence PDE4 inhibitors would decrease the amount of [3H]5'-AMP
formed.
Reactions are performed in duplicate by the addition of 10 pl PDE4 enzyme (U937 lysate or recombinant hPDE4) to 20 pL of assay mix and 20 pL of test compounds in Isoplates (Wallac) for 30 minutes, at 37 C. The final assay mixture contained: 50 mM
Tris (pH
7.5), 8.3 mM MgCl2, 1.7 mM EGTA and [3H]cAMP (0.025 pCi) (Amersham). Assay is terminated by addition 25 pL SPA beads. The plate is sealed, shaken for 1 minute and then allowed to settle 30 minutes and the cpm is determined using a Wallac Micobeta.
Method B:
PDE4 assay based on modified procedure of Thompson and Appleman (Biochemistry (1971); 10; 311-316). In this assay, PDE4 enzymes converts [3H]cAMP to [3H]5'-AMP.
The [3H]5'-AMP is then converted to [3H]adenosine and phosphate by nucleotidase. The amount of [3H]adenosine formed is proportional to the PDE4 activity, hence inhibitors would decrease the amount off H]adenosine formed.

PDE reactions are performed for 30 minutes at 37 C in 100 pL volumes in 1 pM
cAMP, 0.05 pCi [3H]cAMP (Amersham), 0.5 U/mL 5'-nucleotidase (Sigma), 50 mM Tris, 10 mM
MgCl2 pH 7.5. Reactions are performed in duplicate. Reactions are terminated by boiling for 2 minutes at 100 C followed by the addition of 200 pL Dowex 1-8 400 Cl-anion exchange resin in a ratio of 1 resin:2 methanol:1 H2O. Samples are mixed by inversion and then allowed to settle for 2-3 hours. An aliquot of 75 pL is transferred to Isoplates (Wallac), 150 pL of scintillation fluid added and the plate sealed and shaken for minutes. The cpm is determined using a Wallac Micobeta.

Compounds of invention are dissolved in 100% DMSO and diluted such that the final 3o DMSO concentration in the assay does not exceed 1% to avoid affecting the activity. PDE4 enzyme is added in quantities such that less than 15% of substrate is consumed (linear assay conditions). Test compounds are assayed at 6-8 concentrations ranging from 0.1 nM to 30 pM and IC50 values are determined from the concentration curves by nonlinear regression analysis (GraphPad Prism 4).

Compounds of the invention, when tested in these assays, demonstrate the ability to inhibit PDE4 phosphodiesterase activity.

Measurement of Cyclic AMP PDE7 activity The PDE7 assay is based on a modified procedure if the phosphodiesterase [3H]cAMP
SPA Enzyme Assay (Amersham Biosciences code TRKQ 7090). In this assay, PDE7 enzyme(s) convert [3H]cAMP to [3H]5'-AMP. The assay is quenched by the addition of ice-cold SPA yttrium silicate beads which preferentially binds linear nucleides, eg 5'-AMPover cycling nucleotides in the presence of zinc sulphate. The amount of [3H]5'-AMP formed is proportional to the activity of the PDE7, and hence inhibitors of the enzyme would decrease the amount of [3H]5'-AMP formed.
Reactions are performed in duplicate by the addition of 15 pL of PDE7 (Baculovirus lysate) to 10 pL of assay mix and 25 pL test compounds in 96-well flat-bottom plate for 60 min at ambient temperature. The Assay mixture contains 50 mM Tris (pH 7.5), 8.3 mM MgCl2, 1.7 mM EGTA and [3H]cAMP (0.025 pCi) (Amersham). The assay is terminated by addition 25 pL SPA beads. The plate is sealed, shaken for 1 minute and then allowed to settle for 20 to 45 minutes and the cpm is determined using a Packard Topcount Scintillation counter.

Compounds of the invention may inhibit PDE7, as demonstrated by the above assay.
PBMC cell assay Peripheral blood mononuclear cells (PBMC) were isolated from healthy volunteers and dissolved in RPMI 1640 to a final cell concentration of 1,33x106 cells/mL.
0,2% Fetal bovine serum (FBS) was added to the cell suspension.

1. The PBMC cells in 384 well microtiter plate (100 000 cells/ well) were induced with 2 mg/mL lipopolysaccharide (LPS) giving a final concentration of 10 pg/mL.
2. IC5o curves were run in duplicate with 10 different concentrations of compound.
1,5 pL of compound in DMSO were added to each well.
3. The cells were incubated with substance for 18 h at 37 C and 5% CO2 in a humidified chamber.
4. Incubation was terminated at -80 C for at least one hour.
5. 10 pL of assay solution is transferred into a low volume 384-well plate.
TNF-a was detected according to Cisbio's TNF-a HTRF assay (Cisbio, ref no 62TNFPEB). The cell assay was incubated with 5 pL of each HTRF reagent during 3 h. The amount of TNF-a was detected on a Tecan Saphire 2.

6. IC50 curves were fitted with GraphPad Prism software.

Examples Chemicals employed in the synthesis of the compounds in the examples may be commercially available from, e.g. Sigma-Aldrich Fine Chemicals or Acros or Int. Alfa Aesar, Menai Organics, Chembrige and Matrix Scientific.

The invention is illustrated by way of the following examples, in which the following abbreviations may be employed:

aq aqueous Boc tert-butyloxycarbonyl conc concentrated DCM dichloromethane DMSO dimethylsulphoxide DMF N,N-dimethylformamide EtOAc ethyl acetate EtOH ethanol MeCN acetonitrile MeOH methanol MS mass spectrometry NMR nuclear magnetic resonance rt room temperature Pd/C Palladium on activated carbon Intermediate A
5-(3-Cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one (a) 2-(3-Cyclopentyloxy-4-methoxyphenyl)-3-(dimethylamino)acrylaldehyde Me2N
H
A -r-\

MeO
POC13 (15 g, 9.3 mL, 100 mmol) was added to a solution of 2-(3-cyclopentyloxy-methoxyphenyi)acetic acid (10 g, 40 mmol) in DMF (50 mL). The mixture was stirred at 70 C for 18 h. After cooling to rt the mixture was poured into a stirred aq solution of K2CO3 (2 M, 200 mL, 400 mmol). NaOH (10 g, 250 mmol) was added in portions to the stirred mixture. After the NaOH had dissolved, the mixture was extracted with toluene.
The combined extracts were washed with brine, dried over Na2SO4 and concentrated to give the sub-title compound which was used in the next step without further purification.
MS (m/z): 290 (M+H+).
1 H NMR (DMSO-d6, 400 MHz): 5 8.93 (s, 1 H), 7.08 (br. s, 1 H), 6.87 (d, 1 H), 6.60 (d, 1 H), 6.57 (dd, 1H), 4.75-4.79 (m, 1H), 3.73 (s, 3H), 2.80 (br. s, 6H), 1.87-1.77 (m, 2H), 1.75-1.65 (m, 4H), 1.60-1.50 (m, 2H).

(b) 5-(3-Cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one H

MeO
A solution of HCI in EtOH (1.25 M, 48 mL, 60 mmol) was added to a mixture of the 2-(3-cyclopentyloxy-4-methoxyphenyl)-3-(dimethylamino)acrylaldehyde from the previous step, urea (4.8 g, 80 mmol) and EtOH (200 mL). The mixture was stirred at 70 C for 3 h.
After cooling to rt the mixture was concentrated and the product was precipitated by addition of water (-20 mL). Recrystallization from EtOH gave the sub-title compound.
Yield 4.3 g (38 % from 2-(3-cyclopentyloxy-4-methoxyphenyl)acetic acid).
MS (m/z): 287 (M+H+).
1H NMR (DMSO-d6, 400 MHz): 6 12.14 (s, 1H), 8.56 (br. s, 2H), 7.15 (d, 1H), 7.10 (dd, 1 H), 6.98 (d, 1 H), 4.95-4.90 (m, 1 H), 3.75 (s, 3H), 1.95-1.84 (m, 2H), 1.77-1.67 (m, 4H), 1.62-1.52 (m, 2H).

Intermediate B
5-(3-Cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one HNINH

I\
O
MeO
A mixture of 5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one (1.97 g, 6.87 mmol), Pd/C (10 %, 500 mg) and EtOH (200 mL) was hydrogenated at ambient temperature and pressure for 2 d. The mixture was filtered through Celite and concentrated to give the sub-title compound. Yield 1.91 g (96 %).

MS (m/z): 291 (M+H+), 1H NMR (CDC13, 400 MHz): 6 6.82 (d, 1 H), 6.75-6.71 (m, 2H), 5.48 (d, 2H), 4.77-4.72 (m, 1H), 3.82 (s, 3H), 3.47-3.37 (m, 4H), 3.16-3.08 (m, 1H), 1.96-1.78 (m, 6H), 1.66-1.56 (m, 2H).
Intermediate C
5-Fluoro-2-iodomethylbenzoxazole The title compound was prepared as described in international patent application W02008/110793, section "Synthetic Preparation of Intermediates of Formula III", Preparation Route 1.

Intermediate D
tert-Butyl 2-iodomethylbenzimidazole-1-carbox Irate The title compound was prepared as described in international patent application W02008/110793, section "Synthetic Preparation of Intermediates of Formula III", Preparation Route 8.

Intermediate E
2-Bromometh yl-5-methoxybenzofuran The title compound was prepared as described in international patent application W02008/110793, section "Synthetic Preparation of Intermediates of Formula III", Preparation Route 11.

Intermediate F
4-Fluoro-2-iodomethylbenzoxazole The title compound was prepared in accordance with international patent application W02008/110793, section "Synthetic Preparation of Intermediates of Formula III", Preparation Route 1, from 2-amino-3-fluorophenol.

Intermediate G
7-Fluoro-2-iodomethylbenzoxazole The title compound was prepared as described in international patent application W02008/110793, section "Synthetic Preparation of Intermediates of Formula III", Preparation Route 1.

Intermediate H
6-Fluoro-2-iodomethylbenzoxazole The title compound was prepared in accordance with international patent application W020081110793, section "Synthetic Preparation of Intermediates of Formula III", Preparation Route 1, from 2-amino-5-fluorophenol.
Intermediate I
2-(Iodomethyl)benzoxazole-4-carbonitrile The title compound was prepared as described in international patent application W02008/110793, section "Synthetic Preparation of Intermediates of Formula III", Preparation Route 5.

Intermediate J
2-(Iodomethyl)benzoxazole-7-carbonitrile The title compound was prepared in accordance with international patent application W02008/110793, section "Synthetic Preparation of Intermediates of Formula III", Preparation Route 5, from 2-hydroxybenzonitrile.

Example 1 5-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(5-fluorobenzoxazol-2_ylmethyl)pyrimidin-2-one NaH (60 % suspention in oil, 20 mg, 0.5 mmol) was added to a solution of Intermediate A
(115 mg, 0.4 mmol) in DMF (10 mL) at rt. After stirring for 1 h, Intermediate C (139 mg, 0.5 mmol) was added and the mixture was stirred at rt for 1 h. Ice-cold water was added and the mixture was extracted with DCM. The combined extracts were washed with brine, dried over Na2SO4 and concentrated. Crystallization of the residue from MeCN
gave the sub-title compound. Yield and spectroscopic data are listed in Table 1.

Example 2 5-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(5-fluorobenzoxazol-2-ylmethyl)tetra-hydropyrimidin-2-one A mixture of the 5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(5-fluorobenzoxazol-2-ylmethyl)pyrimidin-2-one (87 mg, 0.2 mmol, see Example 1), Pd/C (10 %, 50 mg) and EtOH (50 mL) was hydrogenated at ambient temperature and pressure for 2 d. The mixture was filtered through Celite and concentrated. Crystallization of the residue gave the title compound. Yield and spectroscopic data are listed in Table 1.

Example 3 tert-Butyl 2-(5-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrimidin-1-ylmethyl)benzimidazole-1-carboxylate The title compound was prepared in accordance with Example 1 from Intermediates A
and D. Yield and spectroscopic data are listed in Table 1.

Example 4 tert-Butyl 2-(5-(3-cyclopentyloxy-4-methoxvphenyl)-2-oxotetrahydropyrimidin-l -yl-methyl)benzimidazole-1-carboxylate The title compound was prepared in accordance with Example 2 from tert-butyl 2-(5-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrimidin-1-ylmethyl)benzimidazole-1-carboxylate (see Example 3). Yield and spectroscopic data are listed in Table 1.
Example 5 5-(3-Cyclopentyloxy-4-methoxvphenyl)-1-(5-methoxybenzofuran-2-ylmethyl)-tetrahydropyrimidin-2-one The title compound was prepared in accordance with Example 1 from Intermediates B
and E. Yield and spectroscopic data are listed in Table 1.

Example 6 1-(Benzimidazol-2-yimethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one Trifluoroacetic acid (1.5 mL) was added to a mixture of tert-butyl 2-((5-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxotetrahydropyrimidin-1-yl)methyl)benzimidazole-1-carboxylate (190 mg, 0.37 mmol, see Example 4) and DCM (15 ml-) and the mixture was stirred at rt for 4 h. Concentration gave the title compound. Yield and spectroscopic data are listed in Table 1.

Example 7 5-(3-(Cyclopentyloxy)-4-methoxvphenvl)-1-((4-fluorobenzoxazol-2-yl)meth ll)pyrimidin-2-one The title compound was prepared in accordance with Example 1 from Intermediates A
and F. Yield and spectroscopic data are listed in Table 1.

Example 8 5-(3-(Cyclopentyloxy)-4-methoxvphenvl)-1-((7-fluorobenzoxazol-2- l)y methyl)pyrimidin-2-one The title compound was prepared in accordance with Example 1 from Intermediates A
and G. Yield and spectroscopic data are listed in Table 1.

Example 9 5-(3-(Cyclopentyloxy)-4-methoxvphenvl)-1-((4-fluorobenzoxazol-2-yl)methyl)-tetrahydropyrimidin-2-one The title compound was prepared in accordance with Example 2 from 5-(3-(cyclopentyloxy)-4-methoxyphenyl)-1-((4-fluorobenzoxazol-2-yl)methyl)pyrimidin-2-one (see Example 7). Yield and spectroscopic data are listed in Table 1.

Example 10 5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-1-((6-fluorobenzoxazol-2-yI)methyl)pyrimidin-2-one The title compound was prepared in accordance with Example 1 from Intermediates A
and H. Yield and spectroscopic data are listed in Table 1.

3o Example 11 5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-1-((7-fluorobenzoxazol-2-yl)methyl)-tetrahydropyrimidin-2-one The title compound was prepared in accordance with Example 2 from 5-(3-(cyclopentyloxy)-4-methoxyphenyl)-1 -((7-fluorobenzoxazol-2-yl)methyl)pyrimidin-2-one (see Example 8). Yield and spectroscopic data are listed in Table 1.

Example 12 5-(3-(Cvclopentvloxv)-4-methoxyphenvl)-1-((6-fluorobenzoxazol-2-yl)methyl)-tetrahydropyrimidin-2-one The title compound was prepared in accordance with Example 2 from 5-(3-(cyciopentyloxy)-4-methoxyphenyl)-1-((6-fluorobenzoxazol-2-yl)methyl)pyrimidin-2-one (see Example 10). Yield and spectroscopic data are listed in Table 1.

Examples 13 and 14 (R)- and (S)-5-(3-Cvclopentvloxv-4-methoxyphenvl)-1-(5-fluorobenzoxazol-2yl-methyl)pyrimidin-2-ones The title compounds where prepared by separation of racemic 5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-fluorobenzoxazol-2-ylmeth ylpyrimidin-2-one (see Example 1) using preparative HPLC (column: Phenomenex Lux 5p Cellulose-2; eluent:
isopropanol:isohexane, 10:90). The compound of Example 13 had lower retention time.
The spectroscopic data of the enantiomers are identical to those of the racemate (see Example 1). The absolute configurations were not determined.

Example 15 5-(3-(Cvclopentvloxv)-4-methoxyphenvl)-1-((1 3-dimethylpyrazol-5-yl)methyl)pyrimidin-2-one KI (1.2 g, 7.2 mmol) was added to a solution of 5-chloromethyl-1,3-dimethylpyrazole (415 mg, 2.9 mmol) in DMF (10 mL) and the mixture was stirred at rt for 30 min.
Intermediate A (822 mg, 2.9 mmol) followed by NaH (60 % suspention in oil, 287 mg, 7.2 mmol) were added and the mixture was stirred at rt for 1 h. The mixture was quenched with icecold water (20 mL) and extracted with DCM (3x20 mL). The combined extracts were washed with brine (20 mL), dried over Na2SO4 and concentrated. Crystallization from MeCN gave the title compound. Yield and spectroscopic data are listed in Table 1.

Example 16 5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-1-((1 3-dimethylpyrazol-5- Iy )methyl)-tetrahydropyrimidin-2-one The title compound was prepared in accordance with Example 2 from 5-(3-(cyclopentyloxy)-4-methoxyphenyl)-1-((1,3-dimethylpyrazol-5-yl)methyl)pyrimidin-2-one (see Example 15). Yield and spectroscopic data are listed in Table 1.

Example 17 1-((2-Chlorothiazol-5-yl)methyl)-5-(3-(cyclopentyloxy)-4-methoxyphenyl)pyrimidin-2-one The title compound was prepared in accordance with Example 15 from Intermediate A
and 2-chloro-5-(chloromethyl)thiazole. Yield and spectroscopic data are listed in Table 1.
Example 18 2-((5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-oxopyrimidin-1 -yl)methyl)benzoxazole-4-carbonitrile The title compound was prepared in accordance with Example 1 from Intermediates A
and I. Yield and spectroscopic data are listed in Table 1.

Examples 19 and 20 2-((5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-oxo-2,3-dihydropyrimidin-l-yl)-methyl)benzoxazole-4-carbonitrile and 2-((5-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-oxotetrahydropyrimidin-i-yl)methyl)benzoxazole-4-carbonitrile A mixture of the title compounds was prepared in accordance with Example 2 from 2-((5-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-oxopyrimidin-1-yl)methyl)benzoxazole-4-carbonitrile (see Example 18). The title compounds were obtained by separation using preparative HPLC (column: Agilent XDB-C18; eluent: MeCN:water gradient, 5:95 -100:0). Yields and spectroscopic data are listed in Table 1.

Example 21 2-((5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-oxopyrimidin-1-yl)methyl)benzoxazole-7-carbonitrile The title compound was prepared in accordance with Example 1 from Intermediates A
and J. Yield and spectroscopic data are listed in Table 1.

Examples 22 and 23 (5-(3-(Cyclopentyloxy)-4-methox yphenyl)-2-oxo-2 3-dihydropyrimidin-1-yl)-methyl)benzoxazole-7-carbonitrile and 2-((5-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-oxotetrahydropyrimidin-1-yl)methyl)benzoxazole-7-carbonitrile A mixture of the title compounds was prepared in accordance with Example 2 from 2-((5-(3-(cyclopentyloxy)-4-methoxyphenyl)-2-oxopyrimidin-1-yl)methyl)benzoxazole-7-carbonitrile (see Example 21). The title compounds were obtained by separation using preparative HPLC (column: Agilent XDB-C18; eluent: MeCN:water, gradient 5:95 -100:0). Yields and spectroscopic data are listed in Table 1.

Table 1.
Chemical structure MS (m/z) Yield (%) Ex. Name NMR

Nk N
F
~
436 (M+H+) 40 1 o10 MeO
1 5-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(5-fluorobenzoxazol-2-yl-methyl)pyrimidin-2-one 'H NMR (DMSO-d6, 400 MHz) 6 9.06 (d, 1 H), 8.72 (d, 1 H), 7.80 (dd, 1 H), 7.62 (dd, 1 H), 7.27 (ddd, 1 H), 7.19 (d, 1 H), 7.16 (dd, 1 H), 7.04 (d, 1H), 5.48 (s, 2H), 4.94-4.89 (m, 1H), 3.77 (s, 3H), 1.96-1.85 (m, 2H), 1.77-1.67 (m, 4H), 1.62-1.52 (m, 2H) NINH
F / o 2 440 (M+H+) 41 o10 MeO

5-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(5-fluorobenzoxazol-2-yl-methyl)tetrahydropyrimidin-2-one Chemical structure JMS (m/z) Yield (%) Ex. Name NMR
'H NMR (DMSO-d6, 400 MHz) 8 7.73 (dd, 1 H), 7.60 (dd, 1 H), 7.24 (ddd, 1 H), 6.89 (d, 1 H), 6.87 (d, 1 H), 6.81 (dd, 1 H), 6.70 (d, 1 H), 4.82 (d, 1 H), 4.79-4.74 (m, 1 H), 4.68 (d, 1 H), 3.70 (s, 3H), 3.59 (dd, 1 H), 3.51 (ddd, I H), 3.38-3.26 (m, 2H), 3.24-3.16 (m, I H), 1.90-1.80 (m, 2H), 1.74-1.63 (m, 4H), 1.59-1.50 (m, 2H) ~Of N j ~~j 417 (M-Boc+H) 74 ,0 MeO

3 tert-Butyl 2-(5-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxopyrimidin-1-ylmethyl)benzimidazole-1-carboxylate ' H NMR (DMSO-d6, 400 MHz) 6 9.07 (d, 1H), 8.62 (d, I H), 7.94 (d, 1H), 7.63 (d, 1H), 7.40 (ddd, 1H), 7.32 (ddd, 1H), 7.19-7.15 (m, 2H), 7.03 (d, 1H), 5.63 (s, 2H), 4.93-4.88 (m, 1H), 3.77 (s, 3H), 1.95-1.85 (m, 2H), 1.77-1.67 (m, 4H), 1.73 (s, 9H), 1.60-1.52 (m, 2H) o~o o N-111-,~ N~NH

421 (M-Boc+H+) 99 o We tert-Butyl 2-(5-(3-cyclopentyloxy-4-methoxyphenyl)-2-oxotetrahydro-4 pyrimidin-1-y1methyl)benzimidazole-1-carboxylate 'H NMR (DMSO-d6, 400 MHz) 8 7.93-7.89 (m, 1 H), 7.71-7.67 (m, 1 H), 7.38-7.30 (m, 2H), 6.91 (d, 1H), 6.88 (d, 1H), 6.82 (dd, 1H), 6.57 (d, 1 H), 4.93 (d, 1 H), 4.88 (d, 1 H), 4.81-4.76 (m, 1 H), 3.70. (s, 3H), 3.71-3.65 (m, 1H), 3.55-3.49 (m, 1H), 3.41-3.26 (m, 3H), 1.90-1.81 (m, 2H), 1.75-1.64 (m, 4H), 1.67 (s, 9H), 1.59-1.50 (m, 2H) Chemical structure MS (m/z) Yield (%) Ex. Name NMR

NNH
Me0 / , O
451 (M+H+) 14 I~ 10 MeO

5-(3-Cyclopentyloxy-4-methoxyphenyl)-1-(5-methoxybenzofuran-2-yl-methyl)tetrahydropyrimidin-2-one 'H NMR (DMSO-d6, 400 MHz) S 7.41 (d, 1H), 7.06 (d, 1H), 6.87-6.82 (m, 3H), 6.77 (dd, 1 H), 6.63 (s, 1 H), 6.58 (d, 1 H), 4.75-4.70 (m, 1 H), 4.66 (d, 1 H), 4.51 (d, 1 H), 3.75 (s, 3H), 3.69 (s, 3H), 3.42-3.26 (m, 2H), 3.34-3.28 (m, 1 H), 3.27-3.21 (m, 1 H), 3.15-3.07 (m, 1 H), 1.86-1.77 (m, 2H), 1.73-1.60 (m, 4H), 1.57-1.48 (m, 2H) N NNH
NH
(~ 421 (M+H+) 99 MeO

6 1 -(Benzimidazol-2-ylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)-tetrahydropyrimidin-2-one 'H NMR (DMSO-d6, 400 MHz) 5 7.82-7.77 (m, 2H), 7.55-7.50 (m, 2H), 6.91 (d, 1 H), 6.89 (d, 1 H), 8.87 (d, 1 H), 6.80 (dd, 1 H), 4.90 (d, 1 H), 4.86 (d, 1 H), 4.79-4.74 (m, 1 H), 3.71 (s, 3H), 3.68 (dd, 1 H), 3.57 (ddd, 1 H), 3.40-3.25 (m, 3H), 1.90-1.80 (m, 2H), 1.75-1.64 (m, 4H), 1.60-1.50 (m, 2H) F NI N
/ \ o 1 7 I ,0 436 (M+H+) 50 o MeO

5-(3-(Cyclopentyloxy)-4-methoxyphenyi)-1-((4-fiuorobenzoxazol-2-yl)-methyl)pyrimidin-2-one Chemical structure MS (m/z) yield (%) Ex. Name NMR
'H NMR (DMSO-d6, 400 MHz) 6 9.08 (d, 1 H), 8.73 (d, 1 H), 7.64 (dd, 1 H), 7.45 (td, 1 H), 7.27 (ddd, 1 H), 7.20 (d, 1 H), 7.18 (dd, 1 H), 7.05 (d, 1H), 5.51 (s, 2H), 4.95-4.90 (m, 1H), 3.78 (s, 3H), 1.97-1.85 (m, 2H), 1.78-1.67 (m, 4H), 1.62-1.52 (m, 2H) F 436 (M+H+) 20 o MeO

8 5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-1-((7-fluorobenzoxazol-2-yl)-methyl)pyrimidin-2-one 'H NMR (DMSO-d6, 400 MHz) 6 9.08 (d, 1 H), 8.73 (d, 1 H), 7.58 (dd, 1 H), 7.43-7.34 (m, 2H), 7.20 (d, 1 H), 7.18 (dd, 1 H), 7.05 (d, 1 H), 5.52 (s, 2H), 4.94-4.89 (m, 1 H), 3.78 (s, 3H), 1.97-1.85 (m, 2H), 1.78-1.67 (m, 4H), 1.62-1.52 (m, 2H) " N NH

440 (M+H+) 98 Meo 9 5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-1-((4-fluorobenzoxazol-2-yI)-methyl)tetrahydropyrimidin-2-one 'H NMR (DMSO-d6, 400 MHz) 6 7.57 (dd, 1 H), 7.40 (td, 1 H), 7.24 (ddd, 1 H), 6.90 (d, 1 H), 6.86 (d, 1 H), 6.81 (dd, 1 H) 6.72 (d, 1 H), 4.85 (d, 1 H), 4.79-4.74 (m, 1 H), 4.71 (d, 1 H), 3.70 (s, 3H), 3.60 (dd, 1 H), 3.53 (ddd, 1 H), 3.33 (dd, 1 H), 3.31-3.27 (m, 1 H), 3.24-3.17 (m, 1 H), 1.89-1.80 (m, 2H), 1.74-1.63 (m, 4H), 1.58-1.50 (m, 2H) N

436 (M+H+) 32 F I \ r-\
MeO

Chemical structure MS (m/z) Yield (%) Ex. Name NMR
5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-1-((6-fluorobenzoxazol-2-yI)-methyl)pyrimidin-2-one ' H NMR (DMSO-d6, 400 MHz) S 9.07 (d, 1 H), 8.72 (d, 1 H), 7.78 (dd, 1 H), 7.75 (dd. 1 H), 7.27 (dd, 1 H), 7.25 (dd, 1 H), 7.19 (d, 1 H), 7.16 (d, I H), 7.05 (d, 1 H), 5.47 (s, 1 H), 4.94-4.90 (m, 1 H), 3.78 (s, 1 H), 1.96-1.87 (m, 2H), 1.78-1.68 (m, 4H), 1.62-1.53 (m, 2H) NNH

440 (M+H+) 99 F

MeO

11 5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-1-((7-fluorobenzoxazol-2-yl)-methyl)tetrahydropyrimidin-2-one 'H NMR (DMSO-d6, 400 MHz) 5 7.57 (dd, 1 H), 7.37 (td, 1 H), 7.32 (ddd, 1 H), 6.90 (d, 1 H), 6.86 (d, 1 H), 6.81 (dd, 1 H), 6.72 (d, 1 H); 4.87 (d, 1 H), 4.79-4.74 (m, 1 H), 4.72 (d, 1 H), 3.70 (s, 3H), 3.60 (dd, 1 H), 3.53 (ddd, 1 H), 3.38-3.32 (m, 1 H), 3.32-3.26 (m, 1 H), 3.25-3.17 (m, 1 H), 1.90-1.79 (m, 2H), 1.74-1.62 (m, 4H), 1.60-1.50 (m, 2H) NNH

440 (M+H+) 99 F r\

Meo 12 5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-1-((6-fluorobenzoxazol-2-yI)-methyl)tetrahydropyrimidin-2-one 'H NMR (DMSO-d6, 400 MHz) S 7.73 (dd, 1 H), 7.69 (dd, 1 H), 7.23 (ddd, 1 H), 6.89 (d, 1 H), 6.86 (d, 1 H), 6.80 (dd, 1 H), 6.70 (d, 1 H), 4.83 (d, 1 H), 4.79-4.74 (m, 1 H), 4.68 (d, 1 H), 3.70 (s, 3H), 3.57 (dd, 1 H), 3.51 (ddd, 1 H), 3.37-3.32 (m, 1 H), 3.32-3.26 (m, 1 H), 3.23-3.16 (m, 1H), 1.90-1.79 (m, 2H), 1.74-1.63 (m, 4H), 1.59-1.50 (m, 2H) Chemical structure MS (m/z) JYield (%) Ex. Name NMR

N
N-N
395 (M+H+) 50 I~ ,0 o MeO

15 5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-1-((1,3-dimethylpyrazol-5-yf)-methyl)pyrimidin-2-one 'H NMR (DMSO-d6, 400 MHz) 6 8.95 (d, 1 H), 8.56 (d, 1 H), 7.14 (d, 1 H), 7.12 (dd, 1 H), 7.02 (d, 1 H), 5.99 (s, 1 H), 5.13 (s, 2H), 4.92-4.90 (m, 1 H), 3.82 (s, 3H), 3.76 (s, 3H), 2.06 (s, 3H), 1.94-1.86 (m, 2H), 1.76-1.68 (m, 4H), 1.63-1.54 (m, 2H) NNH
N-399 (M+H+) 99 1\ O
~ o MeO

16 5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-1-((1,3-dimethyIpyrazol-5-yl)-methyl)tetrahydropyrimidin-2-one 'H NMR (DMSO-d6, 400 MHz) 6 6.85 (d, 1 H), 6.84 (d, 1 H), 6.76 (dd, 1 H), 6.55 (d, 1 H), 5.90 (s, 1 H), 4.75-4.73 (m, 1 H), 4.45 (s, 2H), 3.69 (s, 3H), 3.66 (s, 3H), 3.31-3.19 (m, 4H), 3.09-3.02 (m, 1H), 2.06 (s, 3H), 1.88-1.80 (m, 2H), 1.74-1.62 (m, 4H), 1.59-1.51 (m, 2H) N'Y'NIP

H
ci 418 (M+H+) 13 I~

MeO

17 1-((2-Chlorothiazof-5-yf)methyl)-5-(3-(cyclopentyloxy)-4-methoxy-phenyl)pyrimidin-2-one ' H NMR (DMSO-d6, 400 MHz) 6 8.97 (d, 1 H), 8.68 (d, 1 H), 7.82 (s, 1 H), 7.14 (d, 1 H), 7.11 (dd, 1 H), 7.02 (d, 1 H), 5.26 (s, 2H), 4.93-4.88 (m, 1 H), 3.77 (s, 3H), 1.95-1.85 (m, 2H), 1.78-1.68 (m, 4H), 1.63-1.53 (m, 2H) Chemical structure MS (m/z) Yield (%) Ex. Name NMR

NN

- 443 (M+H+) 36 I\ O
~ o MeO

18 2-((5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-oxopyrimidin-l-yl)-methyl)benzoxazole-4-carbonitrile 'H NMR (DMSO-d6, 400 MHz) 6 9.09 (d, 1 H), 8.74 (d, 1 H), 8.17 (dd, 1 H), 7.92 (dd, 1 H), 7.60 (dd, 1 H), 7.21 (d, 1 H), 7.19 (dd, 1 H), 7.05 (d, 1 H), 5.57 (s, 2H), 4.95-4.90 (m, 1 H), 3.78 (s, 3H), 1.97-1.86 (m, 2H), 1.78-1.67 (m, 4H), 1.63-1.52 (m, 2H) N NH

- 445 (M+H+) 16 JD o MeO

19 2-((5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-oxo-2,3-dihydro-pyrimidin-1-yl)methyl)benzoxazole-4-carbonitrile 'H NMR (DMSO-d6, 400 MHz) 6 8.76 (d, 1 H), 8.15 (dd, 1 H), 7.90 (dd, 1 H), 7.57 (dd, 1 H), 6.89 (d, 1 H), 6.87 (d, 1 H), 6.76 (dd, 1 H), 6.63 (d, 1 H), 4.93 (s, 2H), 4.87-4.82 (m, 1 H), 4.32 (s, 2H), 3.71 (s, 3H), 1.90-1.80 (m, 2H), 1.75-1.65 (m, 4H), 1.59-1.50 (m, 2H) N NH

20 - 447 (M+H+) 21 p~o MeO

2-((5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-oxotetrahydropyrimidin-1-yi)methyl)benzoxazole-4-carbonitrile Chemical structure MS (m/z) Yield (%) Ex. Name NMR
'H NMR (DMSO-d6, 400 MHz) 8 8.11 (dd, 1 H), 7.89 (dd, 1 H), 7.56 (dd, 1 H), 6.89 (d, 1 H), 6.87 (d, 1 H), 6.83 (dd, 1 H), 6.74 (d, 1 H), 4.89 (d, 1 H), 4.79-4.74 (m, 1 H), 4.77 (d, 1 H), 3.70 (s, 3H), 3.61 (dd, 1 H), 3.55 (ddd, 1 H), 3.39-3.31 (m, 1 H), 3.31-3.27 (m, 1 H), 3.26-3.18 (m, 1 H), 1.90-1.80 (m, 2H), 1.74-1.62 (m, 4H), 1.59-1.50 (m, 2H) N

443 (M+H+) 99 N
O
Meo 21 2-((5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-oxopyrimidin-1-yl)-methyl)benzoxazole-7-carbonitrile 'H NMR (DMSO-d6, 400 MHz) S 9.08 (d, 1 H), 8.73 (d, 1 H), 8.12 (dd, 1 H), 7.95 (dd, 1 H), 7.57 (t, 1 H), 7.19 (d, 1 H), 7.17 (dd, 1 H), 7,05 (d, 1 H), 5.57 (s, 2H), 4.94-4.89 (m, 1 H), 3.78 (s, 3H), 1.95-1.86 (m, 2H), 1.78-1.67 (m, 4H), 1.62-1.53 (m, 2H) N~NI NH

445 (M+H+) 37 N I
\
\ o~
Meo 22 2-((5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-oxo-2,3-dihydro-pyrimidin-l-yl)methyl)benzoxazole-7-carbonitrile 'H NMR (DMSO-d6, 400 MHz) 8 8.75 (d, 1 H), 8.12 (dd, 1 H), 7.91 (dd, 1 H), 7.56 (t, 1 H), 6.89 (d, 1 H), 6.86 (d, 1 H), 6.74 (dd, 1 H), 6.63 (d, 1 H), 4.93 (s, 2H), 4.87-4.82 (m, 1 H), 4.43 (s, 2H), 3.72 (s, 3H), 1.90-1.80 (m, 2H), 1.75-1.65 (m, 4H), 1.58-1.50 (m, 2H) N~~NNH
o 23 447 (M+H+) 50 N
\\ \ Jam/
Meo Chemical structure MS (m/z) Yield (%) Ex. Name NMR
2-((5-(3-(Cyclopentyloxy)-4-methoxyphenyl)-2-oxotetrahydropyrimidin-1-yl)methyl)benzoxazole-7-carbonitrile 'H NMR (DMSO-d6, 400 MHz) 8 8.11 (dd, 1 H), 7.90 (dd, 1 H), 7.55 (t, 1 H), 6.89 (d, 1 H), 6.87 (d, 1 H), 6.82 (dd, 1 H), 6.74 (d, 1 H), 4.90 (d, 1 H), 4.79-4.75 (m, 1 H), 4.77 (d, 1 H), 3.70 (s, 3H), 3.61 (dd, 1 H), 3.55 (ddd, 1 H), 3.38-3.31 (m, 1 H), 3.31-3.27 (m. 1 H), 3.25-3.18 (m, 1 H), 1.90-1.80 (m, 2H), 1.74-1.63 (m, 4H), 1.59-1.49 (m, 2H) Example 24 The following examples/compounds of the invention are prepared in accordance with the techniques described herein:
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(7-methoxy-2-benzofurylmethyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-fluoro-2-benzofurylmethyl)tetrahydropyri-midin-2-one;
1-(2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5,6-dimethyl-2-benzimidazolylmethyl)tetra-hydropyrimidin-2-one;
1-(2-benzofurylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-thienylmethyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(2-furylmethyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-imidazolylmethyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(1 -methyl-2-imidazolylmethyl)tetrahydropyrimi-din-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-oxazolylmethyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-thiazolylmethyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-indolylmethyl)tetrahydropyrimidin-2-one;
1-(3-benzothienylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
1-(2-benzothiazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;

5-(3-cyciopentyioxy-4-methoxyphenyl)-1-(5-methyl-2-benzoxazolylmethyl)tetrahydro-pyrimidin-2-one;
1-(6-chloro-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-methyl-2-benzoxazolylmethyi)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(6-methyl-2-benzoxazolylmethyl)tetrahydro-pyrimidin-2-one;
1-(1-benzotriazoiylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-nitro-2-benzoxazolylmethyl)tetrahydropyrimi-din-2-one;
1 -(5-cya no-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahyd ropy ri-midin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-fiuoro-2-benzoxazolylmethyl)tetrahydropyri-midin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-trifluoromethyl-2-benzoxazolylmethyl)tetra-hydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-methyl-2-benzoxazolylmethyl)tetrahydropyri-midin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-methoxy-2-benzoxazolylmethyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-methoxy-2-benzoxazoiylmethyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyioxy-4-methoxyphenyl)-1-(4-fiuoro-2-benzoxazolylmethyl)tetrahydropyri-midin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-fiuoro-2-benzoxazolyimethyl)tetrahydropyri-midin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyri-midin-2-one;
1-(7-chloro-2-benzoxazolylmethyl)-5-(3-cyciopentyioxy-4-methoxyphenyl)tetrahydropyri-midin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-trifluoromethyl-2-benzoxazolylmethyl)tetra-hydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-methoxy-2-benzofurylmethyl)tetrahydropyri-midin-2-one;

1-(2-benzimidazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(1 -methyl-2-benzimidazolylmethyl)tetrahydro-pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(5,6-dichloro-2-benzimidazolylmethyl)tetra-hydropyrimidin-2-one;
1-(4-acetamidoxy-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetra-hydropyrimidin-2-one;
31(7-acetamidoxy-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)tetra-hydropyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-difluoromethoxyphenyl)tetra-hydropyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-trifluoromethoxyphenyl)tetra-hydropyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-[4-difluoromethoxy-3-(3-tetrahydrofuranyloxy)-phenyl]tetrahydropyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-[4-methoxy-3-(3-tetrahydrofuranyloxy)phenyl]-tetrahydropyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-[4-trifluoromethoxy-3-(3-tetrahydrofuranyloxy)-phenyl]tetrahydropyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-methoxy-2-benzofuryimethyl)pyrimid in-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(7-fluoro-2-benzofurylmethyl)pyrimidin-2-one;
1-(2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5,6-dimethyl-2-benzimidazolylmethyl)pyrimidin-2-one;
1-(2-benzofurylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-thienylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-furylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-imidazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(1-methyl-2-imidazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-oxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(2-thiazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(3-indolylmethyl)pyrimidin-2-one;
1-(3-benzothienylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
1-(2-benzothiazoiylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-methyl-2-benzoxazolylmethyl) pyrimidin-2-one;

1-(6-chloro-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-methyl-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(6-methyl-2-benzoxazolylmethyl)pyrimidin-2-one;
1-(1-benzotriazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-nitro-2-benzoxazolylmethyl)pyrimidin-2-one;
1-(5-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one 5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-fluoro-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-trifluoromethyl-2-benzoxazolylmethyl)pyrimi-din-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-methyl-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-methoxy-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-methoxy-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-fluoro-2-benzoxazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(7-fluoro-2-benzoxazolylmethyl)pyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one 1-(7-chloro-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyI)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(4-trifluoromethyl-2-benzoxazolylmethyl)pyrimi-din-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5-methoxy-2-benzofurylmethyl)pyrimidin-2-one;
1-(2-benzimidazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1 -(1-methyl-2-benzimidazolylmethyl)pyrimidin-2-one;
5-(3-cyclopentyloxy-4-methoxyphenyl)-1-(5,6-dichloro-2-benzimidazolylmethyl)pyrimidin-2-one;
1-(4-acetamidoxy-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimi-din-2-one;
1-(7-acetamidoxy-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-methoxyphenyl)pyrimi-din-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-difluoromethoxyphenyl)pyrimi-din-2-one;

1-(4-cyano-2-benzoxazolylmethyl)-5-(3-cyclopentyloxy-4-trifluoromethoxyphenyl)pyrimi-din-2-one;
1-(4-cyano-2-benzoxazolylmethyl)-5-[4-difluoro methoxy-3-(3-furanyloxy)phenyl]pyrimidin-2-one;
1 -(4-cyano-2-benzoxazo lylmethyl)-5-[4-methoxy-3-(3-fu ranyloxy)phenyl]pyrimidin-2-one;
1-(4-cyano-2-benzoxazolylmeth yl)-5-[4-trifluorometh oxy-3-(3-furanyloxy)phenyl]pyrimi-din-2-one.

Example 25 1o Title compounds of the Examples were tested in a biological test described above (PBMC cell assay) and were found to inhibit PDE-4. Thus, when the total concentration of title compounds in the assay was 10 NM, the following %-inhibition values where obtained:

Example % inhibition Example 26 Title compounds of the Examples were tested in the biological test described above and were found to inhibit PDE-4. Thus, the following IC50 values where obtained:

Example IC50 Example IC50

Claims (32)

1. A compound of formula (I), wherein the dotted lines each independently represent an optional bond (and when the dotted line between the carbon and nitrogen is present, then R2 is absent, and when the dotted line between the carbon and nitrogen is absent, then R2 is present);

m represents 0, 1, 2, 3, 4 or 5;
n represents 0, 1, 2 or 3;

at least one of R1 and, if present, R2 represents -A1-T z-B1 and the other (if present) represents R5, R3 represents hydrogen, -OR4a, C1-12 alkyl (optionally substituted by one or more substituents selected from =O and X1) or -B2;

R4 and R4a independently represent hydrogen, C1-12 alkyl (optionally substituted by one or more substituents selected from =O and X2) or -B3;

R5 represents hydrogen, C1-12 alkyl (optionally substituted by one or more substituents selected from =O and X) or -B3a, each R6 and each R7 independently represent X4, C1-12 alkyl (optionally substituted by one or more substituents selected from =O and X5) or -B4; or any two R6 groups may be linked together to form a further ring, which is formed either by the two relevant groups being linked together by a direct bond or C1-5 alkylene;

A1 represents C1-12 alkylene (optionally substituted by one or more substituents selected from =O and X6), T z represents a direct bond, -N(R w1)- or -C(O)N(R w2)-;

R w1 and R w2 independently represent hydrogen, C1-12 alkyl (optionally substituted by one or more substituents selected from X7) or -B5;

B1 represents:
1) a monocyclic 5-membered heteroaryl group;
2) a polycyclic heteroaryl group;
3) a polycyclic aryl group; or
4) a heterocycloalkyl group, all four of which are optionally and independently substituted with one or more substituents selected from X8 and, in the case of heterocycloalkyl or any non-aromatic rings of a polycyclic aryl or heteroaryl group, =O;

B2, B3 and B3a independently represent aryl (optionally substituted by one or more substituents selected from X9), heterocycloalkyl (optionally substituted by one or more substituents selected from =O and X10) or heteroaryl (optionally substituted by one or more substituents selected from X11), B4 and B5 independently represent heterocycloalkyl (optionally substituted by one or more substituents selected from =O and X12), X1, X2, X3, X4, X5, X6, X7, X8, X9, X10 X11 and X12 independently represent B6, halo, -CN, -NO2, -Si(R8a)3, -OR9a, -OC(O)-R9b, -N(R9c)R9d, -C(O)R9e, -C(O)OR9f, -C(O)N(R9g)R9h, -N(R9i)C(O)OR8b, -N(R9j)C(O)R8c, -N(R9k)S(O)t R8d, -S(O)t OR8e, -S(O)p R8f, -S(O)t N(R9m)R9n, -N(R9p)C(O)N(R9Q)R9r, -N(R9s)S(O)t OR8g, -OC(O)N(R9t)R9u and/or -OS(O)t R8h, R8a, R8b, R8d, R8f, R8g and R8h independently represent C1-12 alkyl optionally substituted by one or more substituents selected from =O and E1;

R8c R8e R9a, R9b, R9c, R9d, R9e, R9f, R9g, R9h, R9i, R9j, R9k, R9m, R9n, R9p, R9q, R9r, R9s, R9t and R9u independently represent hydrogen or C1-12 alkyl optionally substituted by one or more substituents selected from =O and E2; or any pair of R9c and R9d, R9g and R9h, R9m and R9n, R9q and R9r, and R9t and R9u may be linked together with the nitrogen atom to which they are attached to form a 3-to 8-membered ring, optionally containing one or more unsaturations, optionally containing one or two further heteroatoms, and which ring is optionally substituted by one or more substituents selected from =O, halo and C1-6 alkyl optionally substituted by one or more halo atoms, B6 represents C1-12 alkyl, heterocycloalkyl (which latter two groups are optionally substituted by one or substituents selected from =O and E3), aryl or heteroaryl (which latter two groups are optionally substituted by one or substituents selected from E4), t represents, at each occurrence when used herein, 1 or 2, p represents 0, 1 or 2;

E1, E2, E3 and E4 independently represent halo, -CN, -NO2, -OR10a, -OC(O)-R10b, -N(R10c)R10d, -C(O)R10e, -C(O)OR10f, -C(O)N(R10g)R10h, -N(R10i)C(O)OR11a, -N(R10j)C(O)R11b, -N(R10k)S(O)t1R11c -S(O)t1OR11d, -S(O)p1R11e, -S(O)t1N(R10m)R10n, -N(R10p)C(O)N(R10q)R10r, -N(R10s)S(O)t1OR11f, -OC(O)N(R10t)R10u, -OS(O)t1R11g and/or -Si(R11h)3;

R10a, R10b, R10c, R10d, R10e, R10f, R10g, R10h, R10i, R10j, R10k, R10m, R10n, R10p, R10q, R10r, R10s, R10t, R10u, R11b and R11d independently represent hydrogen or C1-3 alkyl optionally substituted by one or more halo atoms, R11a, R11c, R11e, R11f, R11g and R11h independently represent C1-3 alkyl optionally substituted by one or more halo atoms;

t1 represents, at each occurrence when used herein, 1 or 2;
p1 represents 0, 1 or 2, or a pharmaceutically acceptable salt thereof.

2. A compound as claimed in Claim 1, wherein R1 represents -A1-T z-B1 3. A compound as claimed in Claim 1 or Claim 2, wherein R3 represents -OR4a.

4. A compound as claimed in any one of the preceding claims, wherein R4 and R4a independently represent C1-12 alkyl (optionally substituted by one or more substituents selected from =O and X2) or -B3.
5. A compound as claimed in any one of the preceding claims, wherein each R5 represents C1-6 alkyl (optionally substituted by one or more substituents selected from =0 and X) or hydrogen.
6. A compound as claimed in any one of the preceding claims, wherein each R6 and each R7 independently represent X4 or C1-6 alkyl (optionally substituted by one or more substituents selected from =O and X5).
7. A compound as claimed in any one of the preceding claims, wherein A1 represents unsubstituted C1-6 alkylene.
8. A compound as claimed in any one of the preceding claims, wherein R w1 and R w2 independently represent hydrogen.
9. A compound as claimed in any one of the preceding claims, wherein B1 represents a 5-membered heteroaryl group or a bicyclic heteroaryl group optionally substituted with one or more substituents selected from X8.
10. A compound as claimed in any one of the preceding claims, wherein B2, B3, B3a independently represent phenyl (optionally substituted by one or more substituents selected from X9), a 5- or 6-membered heterocycloalkyl group (optionally substituted by one or more substituents selected from =O and X10) or a 5- or 6-membered heteroaryl group (optionally substituted by one or more substituents selected from X11.)
11. A compound as claimed in any one of the preceding claims, wherein B4 and independently represent a 5- or 6-membered heterocycloalkyl group (optionally substituted by one or more substituents selected from =O and X12).
12. A compound as claimed in any one of the preceding claims, wherein, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11 and X12 independently represent B6, -C(O)OR9f, -S(O)t N(R9m)R9n, -N(R9k)S(O)t R8d -CN, -NO2, halo, -OR9a, -N(R9c)R9d, -C(O)N(R9g)R9h and/or -N(R9j)C(O)R8c; R8a, R8b, R8d, R8e, R8f, R8g and R8h independently represent C1-6 alkyl optionally substituted by one or more substituents selected from E1;
R8c, R9a, R9b, R9c, R9d, R9e, R9f, R9g, R9h, R9i, R9j, R9k, R9m, R9n, R9p, R9q, R9r, R9s, R9t and R9u independently represent hydrogen or C1-6 alkyl optionally substituted by one or more substituents selected from E2; B6 represents C3-8 alkyl, 5- or 6-membered heterocycloalkyl (both of which are optionally substituted by one or more E3 substituents), heteroaryl or, aryl, which latter two groups are optionally substituted by one or more E4 substituents; E1, E2, E3 and E4 independently represent -N(R10k)S(O)t1R11c, -S(O)t1N(R10m)R10n, -NO2, -C(O)OR10f, halo, -CN, -OR10a, -N(R10c)R10d, -C(O)N(R10g)R10h and/or -N(R10j)C(O)R11b; R10a, R10b, R10c, R10d, R10e, R10f, R10g, R10h, R10i, R10j, R10k, R10m, R10n, R10p, R10q, R10r, R10s, R10t, R10u and R11b independently represent hydrogen, -CH3 or -CF3, and/or R11a, R11c, R11d, R11e, R11f, R11g and R11h independently represent -CH3 or -CF3.
13. A compound of formula I as defined in any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use as a pharmaceutical.
14. A pharmaceutical formulation including a compound of formula I, as defined in any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable adjuvant, diluent, carrier or excipient.
15. A compound, as defined in any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use in the treatment of: i) an inflammatory disorder; ii) a disorder in which the modulation of intracellular cyclic adenosine 5'-monophosphate levels within a mammal is desired and/or required, which disorder may be an inflammatory disorder; iii) a disorder associated with pathological conditions that are modulated by inhibiting enzymes associated with secondary cellular messengers;
iv) transplant rejection in a mammal; v) uncontrolled cellular proliferation, and/or vi) a disorder associated with the central nervous system.
16. Use of a compound of formula I, as defined in any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disorder as defined by any of i) to vi) in Claim 15.
17. A compound, as defined in any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, for use in the in treatment of a disease/disorder in which the inhibition of a phosphodiesterase is desired and/or required.
18. Use of a compound of formula I, as defined in any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of a disease/disorder in which the inhibition of a phosphodiesterase is desired and/or required.
19. A compound or use as claimed in Claim 17 or Claim 18, wherein the phosphodiesterase is PDE7 or PDE4.
20. A compound as claimed in Claim 15, 17 or 19 (as dependent on Claims 15 or 17) or a use as claimed in Claim 16, 18 or 19 (as dependent on Claims 16 or 18), wherein the disorder is inflammation, a proliferative disorder or a disease or pathological condition of the central nervous system.
21. A compound or use as claimed in Claim 20, wherein the disorder is ankylosing spondylitis, arthritis, asthma, chronic obstructive pulmonary disease, chronic bronchitis, respiratory distress syndrome, rhinitis, allergic rhinitis, Crohn's disease, nephritis, eczema, atopic dermatitis, urticaria, conjunctivitis, ulcerative colitis, rheumatoid arthritis, osteoarthritis, eosinophilic gastrointestinal disorders, vascular disease, diabetes mellitus, fibromyalgia syndrome, gout, inflammations of the brain, emphysema, inflammatory bowel disease, irritable bowel syndrome, ischemia-reperfusion injury juvenile erythematosus pulmonary sarcoidosis, Kawasaki disease, osteoarthritis, pelvic inflammatory disease, psoriatic arthritis (psoriasis), rheumatoid arthritis, psoriasis, tissue/organ transplant, scleroderma, spondyloarthropathies, systemic lupus erythematosus, pulmonary sarcoidosis, ulcerative colitis, a viral infection, a bacterial infection, cancer, leukemia, a solid tumor, cognitive function, Alzheimer's disease, a learning and memory disorder, cerebrovascular disease, depression, schizophrenia, Parkinson's disease and/or multiple sclerosis.
22. A method of treatment of a disorder as defined by i) to vi) in Claim 15, which method comprises administration of a therapeutically effective amount of a compound of formula I as defined in any one of Claims 1 to 12, or a pharmaceutically-acceptable salt thereof, to a patient suffering from, or susceptible to, such a condition.
23. A method of treatment of a disease/disorder in which the inhibition of a phosphodiesterase is desired and/or required, which method comprises administration of a therapeutically effective amount of a compound of formula I as defined in any one of Claims 1 to 12, or a pharmaceutically-acceptable salt thereof, to a patient suffering from, or susceptible to, such a condition.
24. A method as claimed in Claim 23, wherein the phosphodiesterase is PDE7 or PDE4.
25. A combination product comprising:
(A) a compound of formula I as defined in any one of Claims 1 to 12, or a pharmaceutically-acceptable salt thereof, and (B) another therapeutic agent that is useful in the treatment of a disorder as defined by i), ii), iii), iv), v) or vi) in Claim 15, wherein each of components (A) and (B) is formulated in admixture with a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient.
26 A combination product as claimed in Claim 25 which comprises a pharmaceutical formulation including a compound of formula I as defined in any one of Claims 1 to 12, or a pharmaceutically-acceptable salt thereof, another therapeutic agent that is useful in the treatment of a disorder as defined by i), ii), iii), iv), v) or vi) in Claim 15, and a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient.
27 A combination product as claimed in Claim 25 which comprises a kit of parts comprising components (a) a pharmaceutical formulation including a compound of formula I as defined in any one of Claims 1 to 12, or a pharmaceutically-acceptable salt thereof, in admixture with a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient, and (b) a pharmaceutical formulation including another therapeutic agent that is useful in the treatment of a disorder as defined by i), ii), iii), iv), v) or vi) in Claim 15 in admixture with a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient, which components (a) and (b) are each provided in a form that is suitable for administration in conjunction with the other.
28. A combination product as claimed in any one of Claims 25 to 27, wherein the other therapeutic agent is an inhibitor of a phosphodiesterase.
29. A combination product as claimed in Claim 28, wherein the phosphodiesterase is PDE7 or PDE4.
30 A process for the preparation of a compound of the formula I as defined in Claim 1 which process comprises:
(i) reaction of a compound of formula II, or a protected derivative thereof, wherein R2, R3, R4, R6, R7 and the dotted lines are as defined in Claim 1, with a compound of formula IV, B1-T z-A1-L1 III

wherein L1 represents a suitable leaving group and B1, T z and A1 are as defined in Claim 1, (ii) for compounds of formula I in which the dotted lines are not present and R2 is present and is not H, reaction of a compound of formula I in which the dotted lines are not present and R2 is H with a compound of formula IV, R2a-L2 IV

wherein R2a represents R2 as defined in Claim 1 provided that it does not represent H, and L2 represents a suitable leaving group;
(iii) for compounds of formula I in which the dotted lines are not present and R2 is H, reduction of a compound of formula I in which the dotted lines represent bonds (so forming double bonds in the compound of formula I) or protected derivatives thereof;
(iv) for compounds of formula I in which one or both of the dotted lines represent bonds (so forming one or two double bonds in the compound of formula I), dehydrogenation or oxidation of a compound of formula I in which one or both of the dotted lines are not present and R2 is H, or protected derivatives thereof, (v) for compounds of formula I wherein the dotted lines represent bonds, reaction of a compound of formula V, or a protected derivative thereof, wherein R3, R4 R6 R7 and n are as defined in Claim 1, and ml is 0, 1 or 2 (the skilled person will appreciate that -(R6)m represents two optional R6 substituents, and that the structure of the compound of formula V dictates that these substituents may only be positioned at the carbonyl carbon and or in the .beta. position relative to the carbonyl carbon) and Y1a is -OH or -NY a Y b, where Y a and Y
b are independently alkyl, heterocycloalkyl, aryl and/or heteroaryl, or Y a and Y b may be joined to form a ring optionally containing one or more additional heteroatom, with a compound of formula VI, or a protected derivative thereof, wherein B1, T z and A1 are as defined in Claim 1, (vi) for compounds of formula I where the dotted lines represent bonds, reaction of a compound of formula VII, or a protected derivative thereof, wherein R3, R4, R7 and m are as defined in Claim 1, with a compound of formula VI as defined above, in the presence of an ester of formic acid or the like, (vii) for compounds of formula I in which the dotted lines do not represent bonds and R2 is H, intramolecular reaction of a compound of formula VIII, or a protected derivative thereof, wherein L3 represents a suitable leaving group as defined above in respect of L1, and R3, R4, R7 B1, T z, A1 and n are as defined in Claim 1;
(viii) for compounds of formula I in which the dotted lines do not represent bonds, reaction of a compound of formula IX, or a protected derivative thereof, wherein R1, R2, R3, R4, R6, R7, m and n are as defined in Claim 1, with a compound of formula X, where L4 and L5 independently represent a suitable leaving group;
(ix) for compounds of formula I, reaction of a compound of formula XI, or a protected derivative thereof, where R1, R2, R6, m and the dotted lines are as defined in Claim 1 and L5 represents a suitable leaving group, with a compound of formula XII, or a protected derivative thereof, where R3, R4, R7 and n are as defined in Claim 1, and L6 represents a suitable leaving group;
(x) compounds of formula I, particularly those in which R3 represents -OR4a in which R4a is other than hydrogen, reaction of a compound of formula XIII, or a protected derivative thereof, wherein R1, R2, R6, R7, m, n and the dotted lines are as defined in Claim 1 and L7 represents L x or R3, L8 represents L x or -OR4, and L x represents a suitable leaving group and R3 and R4 are as defined in Claim 1, with a compound of formula XIV, R4x-OH XIV
wherein R4x represents R4 or R4a as defined above (or as defined in Claim 1), (xi) for compounds of formula I in which R3 represents -OR 4a in which R4a is other than hydrogen and/or where R4 is other than hydrogen, reaction of a corresponding compound of formula I in which R3 represents -OH and/or R4 represents hydrogen, with a compound of formula XV, R4y-L9 XV
wherein R4y represents R4 or R4a as required/appropriate, and L9 represents a suitable leaving group, and R4 and R4a are as defined above (or defined in Claim 1);
(xii) for compounds of formula I in which T z represents -N(R w1)-, reaction of a compound of formula XVI, or a protected derivative thereof, wherein L10 represents a suitable leaving group, and R2, R3, R4, R6, R7, m, n and the dotted lines are as defined in Claim 1, with a compound of formula XVII, H-Z a XVII

wherein Z a represents -N(R w1)-B1, and R w1 and B1 are as defined in Claim 1;
(xiii) for compounds of formula I in which T z represents -C(O)-N(R w2)-, reaction of a compound of formula XVIII, or a protected derivative thereof, wherein the dotted lines, R2, R3, R4, R5, R6, R7, A1, m, n and the dotted lines are as defined in Claim 1, with a compound of formula XIX, H-Z b XIX
wherein Z b represents -N(R w2)-B1, and R w2 and B1 are as defined in Claim 1,.
31. A process for the preparation of a pharmaceutical formulation as defined in Claim 14, which process comprises bringing into association a compound of formula I, as defined in any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof with a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient.
32. A process for the preparation of a combination product as defined in any one of Claims 25 to 29, which process comprises bringing into association a compound of formula I, as defined in any one of Claims 1 to 12, or a pharmaceutically acceptable salt thereof with the other therapeutic agent that is useful in the treatment of a disorder as defined by i), ii), iii), iv), v) or vi) in Claim 15, or with an inhibitor of a phosphodiesterase as defined in Claim 28 or Claim 29, and at least one pharmaceutically-acceptable adjuvant, diluent, carrier or excipient.
CA2736970A 2008-09-12 2009-09-10 Pyrimidinone derivatives for use as medicaments Abandoned CA2736970A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US13654008P 2008-09-12 2008-09-12
US61/136,540 2008-09-12
US19383708P 2008-12-30 2008-12-30
US61/193,837 2008-12-30
PCT/GB2009/002169 WO2010029299A1 (en) 2008-09-12 2009-09-10 Pyrimidinone derivaties for use as medicaments

Publications (1)

Publication Number Publication Date
CA2736970A1 true CA2736970A1 (en) 2010-03-18

Family

ID=41381867

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2736970A Abandoned CA2736970A1 (en) 2008-09-12 2009-09-10 Pyrimidinone derivatives for use as medicaments

Country Status (2)

Country Link
CA (1) CA2736970A1 (en)
WO (1) WO2010029299A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116440A1 (en) * 2011-03-03 2012-09-07 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8304413B2 (en) 2008-06-03 2012-11-06 Intermune, Inc. Compounds and methods for treating inflammatory and fibrotic disorders
WO2011114103A1 (en) * 2010-03-18 2011-09-22 Biolipox Ab Pyrimidinones for use as medicaments
MX2014015156A (en) 2012-06-12 2015-08-06 Abbvie Inc Pyridinone and pyridazinone derivatives.
AR092742A1 (en) 2012-10-02 2015-04-29 Intermune Inc ANTIFIBROTIC PYRIDINONES
CA2916653C (en) 2013-06-27 2017-07-18 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
US9828348B2 (en) 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
KR102373700B1 (en) 2014-04-02 2022-03-11 인터뮨, 인크. Anti-fibrotic pyridinones
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
CA3091142C (en) 2018-02-26 2023-04-11 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
BR112022007627A2 (en) 2019-10-25 2022-07-12 Gilead Sciences Inc GLP-1R MODULATE COMPOUNDS
CN115335374B (en) 2020-01-29 2025-05-27 吉利德科学公司 GLP-1R Modulating Compounds
US11851419B2 (en) 2020-11-20 2023-12-26 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2022192430A1 (en) 2021-03-11 2022-09-15 Gilead Sciences, Inc. Glp-1r modulating compounds
US12091404B2 (en) 2021-03-11 2024-09-17 Gilead Sciences, Inc. GLP-1R modulating compounds
AU2022263410B2 (en) 2021-04-21 2024-08-01 Gilead Sciences, Inc. Carboxy-benzimidazole glp-1r modulating compounds
EP4572766A1 (en) 2022-08-18 2025-06-25 Mitodicure GmbH Use of substituted benzoxazole and benzofuran compounds for the treatment and prevention of diseases associated with chronic fatigue, exhaustion and/or exertional intolerance

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
DK1255738T3 (en) * 2000-01-25 2012-06-25 Neurocrine Biosciences Inc Gonadotropin-releasing hormone receptor antagonists and methods related thereto
GB0722769D0 (en) * 2007-11-21 2008-01-02 Biolipox Ab New compounds

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012116440A1 (en) * 2011-03-03 2012-09-07 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
US9688615B2 (en) 2011-03-03 2017-06-27 Degiacomo, Interim Trustee, Mark G. Benzimidazole inhibitors of the sodium channel

Also Published As

Publication number Publication date
WO2010029299A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
CA2736970A1 (en) Pyrimidinone derivatives for use as medicaments
CN107405337B (en) Substituted chromans and methods of use
JP6745824B2 (en) Heterocyclic compound
WO2015113452A1 (en) Compounds
CA2680412A1 (en) Piperidinones useful in the treatment of inflammation
FR2921926A1 (en) QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATIONS THEREOF.
US20180319812A1 (en) Heterocyclic compound
WO2018137573A1 (en) Compounds
US10858367B2 (en) Compounds
WO2018137607A1 (en) Compounds
AU2020401560A1 (en) Antagonists of the muscarinic acetylcholine receptor M4
US20190359618A1 (en) Compounds for inhibiting lrrk2 kinase activity
EP1894930A1 (en) Thiazole derivative
WO2011114103A1 (en) Pyrimidinones for use as medicaments
EP3759091A1 (en) Substituted benzodiazoles and use thereof in therapy
WO2010076564A2 (en) Isochromenones useful in the treatment of inflammation
JP7611900B2 (en) Fused heterocyclic compounds
WO2018137619A1 (en) Compounds
US20240376111A1 (en) Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease
WO2025245472A1 (en) Compounds and related methods useful for degradation of cyclin k and inhibition of cyclin dependent kinases

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130910